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 Zusammenfassung 
Zusammenfassung 
 
Die Interleukin-17 (IL-17) vermittelte Immunantwort spielt eine wichtige Rolle in 
entzündungs-assoziierten Erkrankungen. Aus diesem Grund wurde die Konzentration 
von IL-17 im Serum von Patienten mit Primärem Hepatozellulären Karzinom (HCC) 
vor wenigen Jahren als prognostischer Marker zur Risikoeinschätzung in die Klinik 
eingeführt. In Patienten mit systemischem Lupus Erythematodes, sowie in Mäusen, 
die den Transkriptionsfaktor cAMP-responsive element modulator (CREM)-α in T-
Zellen überexprimieren, konnte gezeigt werden, dass dieser zu einer erhöhten 
Produktion von IL-17 beiträgt. Da infiltrierende Immunzellen und die daraus 
resultierende Hepatitis eine entscheidende Rolle in NemoΔhepa Mäusen, einem 
Mausmodell der chronischen Lebererkrankung, spielen, fragten ich mich ob TH17 
Zellen einen Einfluss auf die Progression der Erkrankung und die daraus 
resultierende Entstehung des HCC haben.  
Um diese Theorie zu überprüfen, wurden Mäuse, die CREMα unter dem CD2 
Promotor überexprimieren, mit hepatozyten-spezifischen Nemo Knockout 
(NemoΔhepa) Mäusen verpaart und im Verlauf der Progression der chronischen 
Lebererkrankung analysiert. 
In 8 Wochen alten Nemo∆hepa/CREMα Mäusen fand ich signifikant reduzierte Serum 
ALT Werte, was mit einer verringerten Anzahl infiltrierender Immunzellen assoziiert 
war. Ergänzend konnte ich mit Hilfe einer Sirius Rot Färbung zeigen, dass die 
Deposition extrazellulärer Matrix in Nemo∆hepa/CREMα Mäusen signifikant reduziert 
war. Infolgedessen wiesen 52 Wochen alte Nemo∆hepa/CREMα Mäuse ein signifikant 
reduziertes Leber-zu-Körpergewicht Verhältnis und weniger HCC auf. 
Da diese Ergebnisse unerwartet waren, war mein nächstes Ziel den zu Grunde 
liegenden Mechanismus zu charakterisieren. Zu diesem Zweck wurden T-Zellen aus 
der Leber isoliert und die Expression immunologisch relevanter Gene mit Hilfe des 
nCounter® Analyse Systems analysiert. Auffällig dabei war eine veränderte 
Expression inhibitorischer T-Zell Epitope, was auf ein verstärktes Vorkommen von 
regulatorischen T-Zellen (Tregs) hindeutete. Daher überprüfte ich diese Resultate 
durch FACS Experimente und konnte, indem ich die Resultate mit denen von 
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peripheren T-Zellen verglich, zusätzlich zeigen, dass der beobachtete Effekt 
spezifisch für die Leber ist.  
Abschließend isolierte ich CREMα transgene T-Zellen und führte einen simultanen 
adoptiven Transfer von T-Zellen und Knochenmarkszellen (co-AT+BMT) durch. In 
Übereinstimmung mit meinen vorherigen Beobachtungen führte die co-AT+BMT 
Technik zu einer reduzierten Leberschädigung und einer verringerten Fibrose in 
Nemo∆hepa Lebern. 
Insgesamt zeigen meine Ergebnisse, dass die Überexpression von CREMα in T-
Zellen den inflammatorischen Status in den Lebern von Nemo∆hepa Mäusen verändert 
und somit die Progression der chronischen Lebererkrankung mildert. Dies führte zu 
einer verringerten HCC-Entstehung. Der protektive Effekt des CREMα Transgens 
konnte in Nemo∆hepa Mäusen durch Transplantationsexperimente bestätigt werden. 
Interessanterweise zeigt die vorliegende Studie, dass das inflammatorische Milieu in 
Lebern von Nemo∆hepa Mäuse zu einer Veränderung des Phänotyps der CREMα 
transgenen T-Zellen in Richtung einer protektiven Treg Antwort führt. 
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 Summary 
Summary 
 
The Interleukin-17 (IL-17)-mediated immune response has been shown to play a 
crucial role in inflammation-associated disease. Actually, serum IL-17 levels have 
been incorporated in the clinic as a risk factor in primary hepatocellular carcinoma 
(HCC) patients. The transcription factor cAMP-responsive element modulator 
(CREM)-α has been shown to contribute to increased IL-17 expression observed in 
patients with systemic lupus erythematosus (SLE) and further in mice expressing 
CREMα in T-cells. Since hepatic inflammation and immune cell infiltration into the 
liver play an essential role in the development of chronic liver injury in Nemo∆hepa 
mice, I reasoned whether TH17 cells might have an impact on disease progression 
and end-stage HCC development. 
Therefore, transgenic mice overexpressing CREMα, controlled by CD2 promoter, 
were crossed with hepatocyte-specific Nemo knockout (Nemo∆hepa) mice and were 
characterized during the progression of chronic liver disease (CLD).  
In 8 week-old Nemo∆hepa/CREMα mice I found significantly decreased serum ALT 
levels, which were associated with reduced numbers of infiltrating cells. Moreover, by 
performing Sirius red staining I demonstrated a significant reduction of extracellular 
matrix (ECM) deposition in Nemo∆hepa/CREMα mice. Consequently, at the age of 52 
weeks Nemo∆hepa/CREMα mice had a significantly reduced liver versus body weight 
ratio and less HCC compared with Nemo∆hepa mice.  
Since these results were unexpected, I further aimed to understand the underlying 
mechanism. I isolated hepatic T-cells and analyzed the expression of numerous 
immunology associated genes using the nCounter® Analysis System. I found an 
altered expression of inhibitory T-cell epitopes, particularly pointing towards an 
increased frequency of regulatory T-cells (Tregs). I confirmed these data using FACS 
analysis and, additionally, by comparing peripheral T-cells, I demonstrated that the 
observed effect seemed to be specific for hepatic T-cells. 
Finally, I isolated CREMα derived T-cells and performed simultaneous adoptive 
transfer of T-cells and bone marrow cells (co-AT+BMT) into Nemo∆hepa mice. In 
agreement with my previous observations, the co-AT+BMT technique caused 
amelioration of liver injury and fibrosis in Nemo∆hepa livers. 
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 Summary 
Overall the results demonstrate that overexpression of CREMα in T-cells changes 
the inflammatory status in livers of Nemo∆hepa mice, and ameliorates the onset and 
progression of CLD. Subsequently, this leads to decreased HCC development. 
Moreover, transplantation experiments validated the protective effect exerted by the 
CREMα transgene in Nemo∆hepa mice. 
Interestingly, this study indicates that the inflammatory milieu in Nemo∆hepa livers 
might be able to induce a shift of CREMα transgene T-cells towards a protective Treg 
response. 
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 Introduction 
1. Introduction 
 
1.1 Liver function and architecture 
 
The liver is the largest internal organ in vertebrates and accounts for 2-5% of the 
human body weight. It constitutes the central organ of the body’s metabolism and is 
responsible for numerous metabolic processes. One main function is the uptake, 
storage and release of carbohydrates, lipids or vitamins. The liver is further 
responsible for the production of bile, coagulation factors and acute-phase proteins. 
Furthermore, the liver degrades and excretes harmful compounds such as bilirubin, 
drugs and toxins (1). For these reasons, the liver is often referred to as a biochemical 
factory. The liver is of high importance to maintain the homeostasis of the whole 
organism. 
All of the above mentioned functions are carried out by liver parenchymal cells, 
namely hepatocytes, which give rise to about 80% of the total liver mass. 
Hepatocytes are organized hexagonally around a central vein and form a single layer 
thick epithelium, thereby generating hepatic lobules - the structural and functional 
units of the liver. The basolateral membrane of the hepatocytes faces the sinusoidal 
blood vessels. This blood possesses low oxygen content but is enriched with 
nutrients. This kind of blood supply is unique and due to the fact that only 25% of the 
blood is supplied via the hepatic artery, the remaining 75% constitute venous blood 
delivered by the portal vein (1). Branches of both vessels are localized in the portal 
areas (Figure 1). The apical membrane of the liver cells forms bile canaliculi which 
transport the bile, generated by hepatocytes, to larger bile ducts. These ducts are 
located in the portal area and exhibit their own epithelium, which is formed by 
cholangiocytes. Thereby the bile is transported into the opposite direction to the 
blood flow (1).  
Several non-parenchymal cell (NPCs) types are located in the sinusoids or in close 
proximity. Kupffer cells (KCs) represent liver resident macrophages which reside 
inside the sinusoids and account for about 2% of the liver cell mass. Quiescent 
hepatic stellate cells (HSCs), also named Ito cells, are Vitamin A storing cells which  
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Figure 1 I Architecture of a hepatic lobule 
Branches of the hepatic artery and the portal vein are localized in portal areas, which are neighboring 
the hepatic lobules, and they release their blood into the sinusoids. The space between the endothelial 
cells of the sinusoids and the hepatocytes is called Disse space.  
Springer and Seminars in Immunopathology, Vol. 31, 2009, Page 399, Liver architecture, cell function 
and disease, Ishibashi et al., Fig.2. With kind permission from Springer Science and Buisness Media 
(2) 
are located in the Disse space, the area between the hepatocytes and the endothelial 
cells, which line the sinusoids (Figure.1). 
Upon injury, these cells get activated and transform into myofibroblasts. These cells 
are the main producers of extracellular matrix (ECM) and thereby highly contribute to 
scar formation and fibrogenesis (1,3). The outstanding importance of the liver is 
further underlined by its unique capability to regenerate after injury (4).  
 
1.1.1 Chronic liver disease (CLD) 
 
Liver injury can have several causes among which hepatitis B (HBV) and C (HCV) 
infections, alcohol or drug abuse and the presence of non-alcoholic steatohepatitis 
(NASH) are the most common. This injury causes inflammation as a part of the 
wound healing response in order to promote regeneration or to antagonize invading 
pathogens. However, persisting inflammation chronically damages the liver and 
triggers liver fibrosis. As a result, fibrotic scars are built throughout the liver thereby 
replacing healthy liver tissue with connective tissue. Fibrogenesis is a reversible 
process, however it can progress to liver cirrhosis, the irreversible end-point of 
chronic liver disease. This process is accompanied by an increasing loss of liver 
function. Therefore compounds such as nutrients, drugs or toxins are no longer 
processed effectively. Additionally, the production of proteins is inhibited and the 
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fibrotic scars impede the blood circulation inside the liver. However, due to its highly 
regenerative potential, the liver is able to compensate the loss of about 80-90% of 
the parenchyma. Thus, clinical symptoms usually appear in late CLD stages. 
Furthermore, in a cirrhotic liver the risk to develop hepatocellular carcinoma (HCC) is 
significantly increased (5,6).  
HCC is the 5th most common cancer and the 3rd leading cause of cancer-related 
deaths (7). Thereby, 90% of HCC develop from underlying cirrhosis. Worldwide, HBV 
infections account for about 50% of HCCs. However, this is mostly attributable to 
Asia and Africa, where these infections are endemic. In Western Countries, HCV 
infections are the major cause of HCC, but also chronic alcohol abuse, obesity and 
diabetes become more and more important risk factors for HCC development. 
Further risk factors are hemochromatosis, drug abuse or the exposure to aflatoxins. 
Additionally, male sex is associated with a higher risk for HCC, as the male to female 
ratio is between 2:1 and 4:1(8,9). Due to the late occurrence of symptoms HCC is 
often diagnosed in late stages where transplantation is the only treatment option. 
 
1.2 NF-κB 
 
NF-κB (nuclear factor-κB) proteins build a family of transcription factors which is 
evolutionarily conserved. They have been first discovered in Drosophila 
Melanogaster where they are critically involved in determining the dorsal-ventral 
patterning of the embryo. In mammals, this protein family consists of five members: 
Rel (c-Rel), RelA (p65), RelB, NF-κB1 (p50 and its precursor p105) and NF-κB2 (p52 
and its precursor p100). The NF-κB proteins are characterized by the presence of a 
Rel homology domain (RHD) which functions in dimerization, DNA binding and 
interaction with Inhibitor of nuclear factor κB (IκBs) proteins. The classical NF-κB is a 
p50/p65 heterodimer but several combinations of the NF-κB family members either 
as homo- or heterodimer exist (10–12). 
The transcription factor NF-κB can be activated due to a variety of stimuli among 
which the pro-inflammatory cytokines TNF-α and IL-1 are the most important. But 
also viral infections, UV-irradiation, lipopolysaccharide (LPS) or B- and T-cell 
activation can lead to NF-κB translocation into the nucleus and subsequently to 
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transcriptional activation. Target genes of NF-κB include cytokines, chemokines, 
adhesion molecules, immuno- and cytokine receptors, acute-phase proteins and 
regulators of apoptosis and cellular proliferation. Therefore NF-κB has an important 
role in regulating the immune response, inflammation and cell growth (10–12). 
Aberrant NF-κB signaling has been implicated to play a fundamental role in 
inflammation-mediated disease like rheumatoid arthritis or asthma. But, furthermore, 
it has been shown that dysregulated NF-κB signaling can lead to the development of 
inflammation-linked cancers such as Hodgkin’s Lymphoma, colitis-associated cancer 
(CAC) and hepatocellular carcinoma (HCC) in humans (13).  
 
1.2.1 The canonical NF-κB signaling pathway 
 
Under unstimulated conditions NF-κB dimers are 
kept inactive by the association with members of 
the IκB family such as IκBα, IκBβ, IκBγ, IκBε and 
Bcl-3. IκBs retain NF-κB in the cytoplasm by 
interacting with the RHD and thereby sterically 
block the function of their nuclear localization 
sequence (NLS) (14).  
The classical signaling pathway, leading to rapid 
NF-κB activation, (Figure 2) is initiated by binding of 
TNF to the Tumor necrosis factor receptor type 1 
(TNFR1). This induces receptor trimerization  
 
                                             
 
 
 
 
Figure 2 I Canonical NFκB signaling pathway 
The classical NFκB signaling pathway is initiated after TNFR1 
stimulation. This leads to aggregation of several intracellular 
signaling molecules including TRADD, TRAF2, TAK1 and 
RIP followed by the activation of the IKK complex. The IKK 
complex phosphorylates IκBs which are in turn ubiquitinated 
and degraded by the proteasome. This leads to the liberation 
of NFκB dimers which can enter the nucleus and regulate 
transcription. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Immunology] (15), copyright (2011). 
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and aggregation of the death domains (DD) leading to the recruitment of several 
intracellular adaptor proteins. Thereby TNFR1-associated death domain protein 
(TRADD) directly binds to TNFR1 and functions as an assembly platform to recruit 
TNFR-associated factor 2 (TRAF2), and receptor interacting protein 1 (RIP1) kinase. 
As a consequence RIP1 gets ubiquitinated which allows the recruitment and 
activation of the Transforming growth factor beta-activated kinase 1 (TAK1) (15,16). 
This subsequently activates the IκB kinase complex (IKK) , which consists of three 
subunits (17). The catalytically active serine kinases IKK1 (IKKα) and IKK2 (IKKβ) 
are 85 kDa respectively 87 kDa proteins (18). They contain a kinase domain in their 
NH2 terminal region and several protein interaction motifs, such as a leucine zipper 
motif and a helix-loop-helix motif, in their COOH-terminal domain (18,19). IKK1 and 
IKK2 form heterodimers and associate with either a dimer or a trimer of the regulatory 
subunit, called Nemo (IKKγ) (17,19). The c-terminal region of Nemo connects IKK1 
and IKK2 to the above mentioned upstream activators and, thus facilitates the 
phosphorylation of IKK2 at serine residues in its T-loop. The activated IKK complex, 
in turn, phosphorylates IκBs at specific Serine (Ser) residues (IκBα: Ser 32/36; IκBβ: 
Ser 19/23) (18–20), thereby targeting them for ubiquitination and finally degradation 
by the 26S proteasome. Therefore the NLS is no longer masked and NF-κB dimers 
are able to enter the nucleus, and to control transcription. 
 
1.2.2 The role of IKKγ in the liver 
 
Nemo is a 48 kDa protein which is encoded by the X-chromosome functioning as the 
regulatory subunit of the IKK complex. Although Nemo lacks the kinase domain it has 
been shown to be essential for NF-κB activation. The prominent features of the IKKγ 
protein are the presence of two extended coiled-coil motifs and a Leu zipper which 
are likely involved in protein-protein interactions. Indeed, it has been demonstrated 
that the c-terminal region of Nemo is necessary to connect the IKK complex to 
upstream activators. Therefore it is not surprising that the absence of Nemo 
completely abolishes IKK and NF-κB activation upon TNF-α treatment in human cell 
lines (17). Constitutive Nemo knockout animals die at day E.13 – E.13.5  
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Figure 3 I Disease progression in Nemo∆hepa mice. 
Disease progression in Nemo∆hepa mice resembles human chronic liver disease. At an age of 8 weeks 
the mice develop severe liver inflammation characterized by hepatocyte apoptosis and compensatory 
proliferation. This further leads to scarring of liver tissue and to fibrosis development, which then 
further progresses into cirrhosis. Finally, 100% of one year old mice develop HCCs (21).  
 
due to breakdown of the liver architecture which is caused by massive hepatocyte 
apoptosis (22). This phenotype resembles the one observed in RelA or IKKβ deficient 
mice although it is more severe in Nemo knockout animals (23–25). Murine 
embryonic fibroblasts isolates from these mice lack NF-κB-binding activity to DNA 
and display a dramatic reduction in viability upon stimulation with TNF-α stimulation.  
However, hepatocyte specific Nemo knockout (NemoΔhepa) mice are born viable but 
develop chronic liver injury characterized by a strong inflammatory response and scar 
formation within the liver leading to liver fibrosis. This process triggers HCC 
development within 52 weeks of age (21). The disease progression of these mice 
thereby resembles the phenotype seen in human CLD (Figure 3). This phenotype 
has been shown to be dependent on spontaneous hepatocyte apoptosis, initiated by 
activation of Caspase-8 (26) and the consequent regenerative response of the liver. 
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1.3 Cre responsive element modulator (CREMα) 
 
CREMα, a 35 kDa big protein, belongs to the family of basic leucine zipper (bZIP)-
transcription factors. They are characterized by the presence of an α-helical coiled-
coil structure and a basic domain, which form a DNA-binding domain and enable  
 
 
Figure 4 I Structure of bZIP transcription factors 
The P-Box is flanked by two glutamine rich domains which together form a transcriptional activation 
domain. The basic leucine zipper serves as DNA-binding and dimerization domain. Adapted from 
Sassone-Corsi et al. 1995 (27). 
 
dimerization (27). They are activated by phosphorylation of the so called P-Box or 
kinase inducible domain (KID). Phosphorylation of the P-Box can be mediated by the 
protein kinase A (PKA) and C (PKC) or the calcium dependent kinase (CAMK) IV and 
II (28,29). The P-Box is flanked by two glutamine rich domains (Q1 and Q2) which, 
together with the P-Box, serve as transcriptional activation domains (27) (Figure 4).  
All bZIP family members bind to cAMP Responsive Elements (CREs), 8 bp 
palindromic DNA-sequences, in the promoter region of cAMP regulated genes such 
as IL-2. But they can either act as transcriptional activators such as Cre response 
element binding protein (CREB) or activating transcription factor (ATF1) or as 
transcriptional repressors such as inducible cAMP early repressor (ICER) or CREMα, 
β, or γ (27,30). CREMα, a transcriptional repressor, is only one isoform generated by 
alternative splicing of the crem gene (30).  
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1.3.1 Active and passive repressor mechanisms of CREMα 
 
To activate transcription, bZIP-family members associate to CREB binding protein 
(CBP) and p300 via the phosphorylated P-Box, which contain histone acetyl 
transferase (HAT) activity. HATs change the acetylation pattern of histones which in 
turn opens the chromatin structure and facilitate the accessibility of the DNA for 
transcription factors. By deacetylation, via histone deacetylases (HDACs), the 
chromatin structure becomes denser and thus inaccessible for restriction enzymes.  
CREMα lacks the Q1 and Q2 domain, which are necessary for transactivation, and 
thus is not able to stimulate the HAT activity of CBP and p300 (31). Furthermore, it 
has been shown that CREMα recruits Histone Deacetylase 1 (HDAC1) to the IL-2 
and c-fos promoters in T-cells and is therefore able to actively repress transcriptional 
activity (32). Finally, due to the lack of the Q2 domain, CREMα is not able to facilitate 
the interaction of CBP and p300 with TATA box binding factor IID (TATIID) (33), 
which is involved in transcriptional initiation by RNA polymerase II.  
 
1.3.2 CREMα in T-cells 
 
CREMα is the most abundant isoform of crem splice variants in T-cells. Together with 
CREB it is a central mediator of T-Cell proliferation by regulating IL-2 expression. 
Once, a T-Cell receives activation signals by engagement of the T-Cell Receptor 
(TCR) and CD28, by an antigen presenting cell, CREMα and CREB are activated by 
phosphorylation. While CREB promotes IL-2 production, CREMα represses it by 
building heterodimers with CREB and thus inactivating it or by competitive 
replacement of CREB at the CRE site respectively (31,34–36).  
T-cells of patients with systemic Lupus Erythematosus (SLE) display an increased 
expression of CREMα and an enhanced binding of CREMα to the -180 site of the IL-
2 promoter (36,37). In these cells, the levels of CREMα mRNA inversely correlate 
with the amounts of IL-2 mRNA. By transfecting SLE T-cells with an antisense 
plasmid for CREMα, IL-2 mRNA and protein levels can be restored (36). It has been 
further demonstrated, that increased expression of CREMα not only represses IL-2 
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transcription but also the transcription of c-fos and CD3ζ (38,39) as observed in T-
cells from SLE patients.  
In order to investigate the underlying mechanisms in SLE patients, mice 
overexpressing CREMα in T-cells (CREMα mice), have been created. T-cells, 
isolated from spleens of theses mice share similarities of T-cells isolated from SLE 
patient, and are characterized by an increased binding of CREMα to the IL-2 
promoter leading to a decrease in IL-2 production and T-cells proliferation (40,41). 
Further, upon stimulation, using anti-CD3 and anti-CD28 antibodies, CREMα T-cells 
show an enhanced production of IL-17 and Retinoid-related orphan receptor-gamma 
t (RORγt), the TH17 lineage transcription factor, in vitro. This was mediated by direct 
binding of CREMα to the IL-17 promoter. These findings were proved using models 
of contact dermatitis and acute lung injury. CREMα animals displayed an increased 
inflammation and an enhanced production of TH17 related cytokines such as IL-17, 
IL-21, IL-22 and IL-23 (40–43).   
A recent study further revealed a role for CREMα in a subset of myeloid derived 
suppressor cells (MDSCs) which have been also shown to express CD2. This study 
demonstrated that CREMα mice are highly susceptible to Concanavalin A (ConA)-
induced hepatitis and display an increased mortality upon treatment due to a reduced 
T-cell suppressive activity of these cells. This effect could be reversed by adoptive 
transfer of Wildtyp (WT) MDSCs into CREMα mice. Interestingly, the authors found 
compartmental differences in the T-cell differentiation pattern between different 
organs as CREMα did not induce a predominant TH17 response in intrahepatic T-
cells (44). 
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1.4 Aim of the study 
 
TH17 cells represent a more recently described subset of CD4+ TH-Cells and are 
characterized by the expression of the lineage determining transcription factor RORγt 
(45) in mice and RORc (46) in humans. TH17 cells have been shown to be 
responsible for the clearance of extracellular bacteria (47,48) and fungi (48,49) but 
they also function as important players in autoimmune diseases such as Rheumatoid 
Arthritis, SLE or Multiple Sclerosis (MS) (50,51). Activated TH17 cells produce IL-
17A, IL-17F, IL-21, IL-22 and TNF-α. These cytokines promote tissue inflammation 
throughout the induction of pro-inflammatory mediators and the recruitment of 
leukocytes, mainly neutrophils (52,53).  
Several lines of evidence indicate an involvement of TH17 in different types of liver 
injury (54). In mice, for example, depletion of the IL-17 signaling either by neutralizing 
antibodies or in IL-17RA KO mice increased fat accumulation of the liver upon high 
fat diet but reduced inflammation and subsequent hepatocyte damage in wild-type 
mice (55). Furthermore, it has been shown that IL-17 signaling is increased in 
response to liver injury and exacerbates CCl4 and BDL induced liver fibrosis in mice 
by promoting HSCs activation and thus enhancing collagen production. 
Consequently, IL-17 KO mice showed reduced inflammation and less severe fibrosis 
development (56,57). Thus, IL-17 is considered not only a pro-inflammatory but also 
a pro-fibrotic cytokine. Moreover, in human liver disease, TH17 cells have been 
shown to be involved in a variety of inflammatory processes including all major 
disease pattern such as alcohol-induced liver injury (ASH) (58), NASH (59,60), viral 
hepatitis (61) and HCC (62–64). Several studies indicate that IL-17 is involved in 
HCC development, for example by promoting angiogenesis (64). Furthermore, 
increased IL-17 levels are associated with a poor prognosis in HCC patients as they 
correlate to a decreased survival and an increased recurrence after hepatectomy in 
those patients (62,63,65).  
Since hepatic inflammation and immune cell infiltration into the liver play an essential 
role in the development of chronic liver injury in NemoΔhepa mice, I focused on the 
analysis of the impact of TH17 cells in disease progression and end-stage HCC 
development. 
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2. Lab equipment and consumables 
 
2.1 Lab equipment 
Table 1 I List of utilized lab equipment and its producer 
Lab Equipment Company 
  
Accu-jet® pro Brand (Wertheim, GER) 
Analytical balance Kern (München, GER) 
Balance Sartorius (Göttingen, GER) 
Benchtop centrifuge Carl Roth (Karlsruhe, GER) 
BioDocAnalyze Biometra (Göttingen, GER) 
Blotting Trans-BlotTM Cell Bio-Rad (Hercules, USA) 
Centrifuge 5415D Eppendorf (Hamburg, GER) 
Centrifuge 5810 R Eppendorf (Hamburg, GER) 
Cooling centrifuge 5417R Eppendorf (Hamburg, GER) 
ELISA Reader µQuant Bio-Tek (Winooski, USA) 
FACS CANTO / FACS Fortessa BD (Franklin Lakes, USA) 
Glaspistill Brand (Wertheim, GER) 
Image Quant™ LAS-4000 Mini Imager FUJIFILM (Düsseldorf, GER) 
Kryostat HM 550 Thermo Scientific (Waltham, USA) 
Magnetic stirrer IKA (Staufen, GER) 
Microscope, Imager Z.1 Zeiss (Göttingen, GER) 
Microscope, Z16 APO Leica (Wetzlar, GER) 
NanoDrop ND 1000 Spectrophotometer peqLab (Erlangen, GER) 
nCounter® GEN2 Prep Station NanoString Technologies (Seattle, USA) 
pH Meter PB-11 Sartorius (Göttingen, GER) 
Pipettes Research® Plus Eppendorf (Hamburg, GER) 
Powersupply PowerPac HC Bio-Rad (Hercules, USA) 
Roller Mixer SRT 9 Sigma-Aldrich (St. Louis, USA) 
SDS PAGE electrophoresis system peqLab (Erlangen, GER) 
Shaking incubator Unimax 1010 Heidolph (Schwabach, GER) 
Thermocycler T3000 Biometra (Göttingen, GER) 
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Lab Equipment Company 
  
Thermomixer 5436 Eppendorf (Hamburg, GER) 
Ultra-Turrax IKA (Staufen, GER) 
Vortexer Heidolph (Schwabach, GER) 
7300 Real-Time PCR System Applied Biosystems (Darmstadt, GER) 
 
2.2 Consumables 
Table 2 I List of utilized consumables and their producer 
Consumables Company 
  
Dako Pen  DAKO (Hamburg, GER) 
Cover slips 24x50mm Carl Roth (Karlsruhe, GER) 
Eppendorf tubes 0.5, 1.5, 2.0 und 5,0ml Eppendorf (Hamburg, GER) 
One way syringe (5ml, 10ml, 20ml) Terumo (Eschborn, GER) 
one way syringe (1 ml) B. Braun (Meslungen, GER) 
needles 23 G, 27 G, 30 G BD (Franklin Lakes, USA) 
LS Columns 
Miltenyi Biotec GmbH (Bergisch Glad-
bach, GER) 
Mikro-Probengefäß 1,3 ml, Kalium-EDTA Sarstedt (Nümbrecht, GER) 
Multiply 8er Strip Sarstedt (Nümbrecht, GER) 
Nitrocellulose Membrane Protran ® GE Healthcare (München, GER)  
Nunc® Cryo Tubes® 1,8ml Thermo Scientific (Waltham, USA) 
Object slide R. Langenbrinck (Emmendingen, GER) 
Instruments for Preparation 
Fine Science Tools GmbH (Heidelberg, 
GER) 
Serum Gel Z Mikroröhrchen Sarstedt (Nümbrecht, GER) 
Tube 13ml Sarstedt (Nümbrecht, GER) 
Round Bottom-(FACS-) Tube 5 ml BD (Franklin Lakes, USA) 
Scalpel (sterile) Feather (Osaka, Japan) 
Glass Capillary 30mm Hilgenberg (Malsfeld, GER) 
Super Frost Plus Objekt slides Thermo Scientific (Waltham, USA) 
Super Frost Objekt slides Carl Roth (Karlsruhe, GER) 
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Consumables Company 
  
Tip One Pipette Tips StarLab (Hamburg, GER) 
Tissue Tek® Cryomold® Sakura (Heppenheim, GER) 
Tissue Tek® uni cassette Sakura (Heppenheim, GER) 
Cell Strainer 70 µm Nylon BD (Franklin Lakes, USA) 
Centrifuge Tube 15 ml nerbe plus (Winsen, GER) 
Centrifuge Tube 50 ml Greiner Bio-One (Frickenhausen, GER) 
6-Well Plates Greiner Bio-One (Frickenhausen, GER) 
24-Well Plates BD (Franklin Lakes, USA) 
96 well Microplates for proteins Greiner Bio-One (Frickenhausen, GER) 
96 well Microplates for RNA (UV-STAR) Greiner Bio-One (Frickenhausen, GER) 
96 well Microplates for RT-PCR StarLab (Hamburg, GER) 
 
2.3 Reagents 
Table 3 I List of utilized reagents and their producer 
Reagent Company 
  
Acetic Acid 100% Merck (Darmstadt, GER) 
Acetone VWR (Radnor, USA) 
Agarose Invitrogen (Paisley, UK) 
Ammonium persulfate (APS) AppliChem (Darmstadt, GER) 
BD Pharm Lyse™ BD (Franklin Lakes, USA) 
Biorad reagent Bio-Rad (Hercules, USA) 
Borgal-Lsg. 24% Virbac (Bad Oldesloe, GER) 
Bromphenolblue Bio-Rad (Hercules, USA) 
BSA (Bovine Serum Albumin) Sigma-Aldrich (St. Louis, USA) 
Calcium chloride (CaCl2) Sigma-Aldrich (St. Louis, USA) 
Caustic soda Merck (Darmstadt, GER) 
Chloroform Merck (Darmstadt, GER) 
Citric Acid Monohydrate (C6H8O7 + H2O) Merck (Darmstadt, GER) 
Complete Mini® (Proteinase Inhibitor  
Cocktail) Roche (Mannheim, GER) 
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Reagent Company 
  
DEPC-Treated Water Life Technologies (Darmstadt, GER) 
Dithiothreitol (DTT) Sigma-Aldrich (St. Louis, USA) 
DNA Marker 1kbplus Ladder® Invitrogen (Paisley, UK) 
ECL Prime Western Blotting Detection 
Reagent 
GE Healthcare (München, GER)  
 
Ethylenediamine tetraacetic acid (EDTA ) 
0,5 M  AppliChem (Darmstadt, GER) 
Eosine AppliChem (Darmstadt, GER) 
Ethanol absolute AppliChem (Darmstadt, GER) 
Ethidiumbromide solution (0,07 %) AppliChem (Darmstadt, GER) 
Fetal Calf Serum (FCS) PAA (Pasching, Austria) 
Forene 100% (Isofluoran) Abbott (Wiesbaden, GER) 
Formaldehyde  4 % (PFA) Fischar (Saarbrücken, GER) 
Formamide AppliChem (Darmstadt, GER) 
Gelatine Type B Sigma-Aldrich (St. Louis, USA) 
Glacial Acetic Acid AppliChem (Darmstadt, GER) 
Glycerol Sigma-Aldrich (St. Louis, USA) 
Glycine AppliChem (Darmstadt, GER) 
Haematoxylin Carl Roth (Karlsruhe, GER) 
Hanks Balanced Salt Solution (HBSS) PAN-Biotech (Aidenbach, GER) 
Hoechst Invitrogen (Paisley, UK) 
Hydrochloric Acid (HCl) Merck (Darmstadt, GER) 
Hydrogen Peroxide (H2O2) 30% AppliChem (Darmstadt, GER) 
Magnesium chloride (MgCl2) Sigma-Aldrich (St. Louis, USA) 
Mayer's acid hemalum Carl Roth (Karlsruhe, GER) 
Mercaptoethanol AppliChem (Darmstadt, GER) 
Methanol VWR (Radnor, USA) 
Mounting Medium VectaShield® Vector (Burlingame, USA) 
Sodium acetate, water free AppliChem (Darmstadt, GER) 
Sodium azide AppliChem (Darmstadt, GER) 
Sodium fluoride (NaF)  Carl Roth (Karlsruhe, GER) 
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Reagent Company 
  
Sodium Carbonate (Na2CO3) Merck (Darmstadt, GER) 
Sodium chloride (NaCl) AppliChem (Darmstadt, GER) 
Nonidet P-40 Substitute (NP40) Sigma-Aldrich (St. Louis, USA) 
Novex® Sharp Pre-stained Protein 
Standard 
Invitrogen (Paisley, UK) 
Paraformaldehyde (PFA) Carl Roth (Karlsruhe, GER) 
PBS 1x (Phosphate buffered saline) PAN-Biotech (Aidenbach, GER) 
PBS 10x pH 7,4 PAN-Biotech (Aidenbach, GER) 
peqGOLD RNAPure peqLab (Erlangen, GER) 
PhosphoStop Roche (Mannheim, GER) 
Picric Acid 1,2 % Chroma Waldeck (Münster, GER) 
Ponceau S Sigma-Aldrich (St. Louis, USA) 
Potassium chloride (KCl) Merck (Darmstadt, GER) 
RNAprotect Cell Reagent Qiagen (Hilden, GER)  
Roti®-Histokitt Carl Roth (Karlsruhe, GER) 
RPMI 1640 Medium PAN-Biotech (Aidenbach, GER) 
Sodium Dodecyl Sulphate (SDS) Carl Roth (Karlsruhe, GER) 
Serum (mouse, human, goat, rabbit) Sigma-Aldrich (St. Louis, USA) 
Sirius Red F3B Chroma Waldeck (Münster, GER) 
TAE-Buffer (50 x) AppliChem (Darmstadt, GER) 
TEMED (N, N, N’, N’-
Tetramethylethylendiamine) Sigma-Aldrich (St. Louis, USA) 
Tissue-Tek® Sakura (Heppenheim, GER) 
Tris Buffer grade AppliChem (Darmstadt, GER) 
Triton X-100 Sigma-Aldrich (St. Louis, USA) 
Tween-20 Sigma-Aldrich (St. Louis, USA) 
Xylene AppliChem (Darmstadt, GER) 
Xylenecyanole Sigma-Aldrich (St. Louis, USA) 
0,1 M DTT Invitrogen (Paisley, UK) 
25 mM EDTA Invitrogen (Paisley, UK) 
30% Acrylamide/Bis Solution Bio-Rad (Hercules, USA) 
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2.4 Enzymes 
Table 4 I List of utilized enzymes and their producer 
Enzyme Company 
  
Collagenase 2, 265u/mg Worthington (Lakewood, USA) 
HotStarTaqTM Master Mix Qiagen (Hilden, GER) 
Proteinase K AppliChem (Darmstadt, GER) 
Ready MixTM Redtaq® PCR Reaction Mix 
with MgCl2 
Sigma-Aldrich (St. Louis, USA) 
SYBR® GreenER q-PCR SuperMix Invitrogen (Paisley, UK) 
 
2.5 Kits 
Table 5 I List of utilized kits and their producer 
Kit Company 
  
Avidin/Biotin Blocking Kit Vector (Burlingame, USA) 
DAB Peroxidase (HRP) Substrate Kit, 
3,3’-diaminobenzidine 
Vector (Burlingame, USA) 
FOXP3 Staining Buffer Set eBioscience (Frankfurt, GER) 
Hot Start Taq Master Mix Kit Qiagen (Hilden, GER) 
In Situ Cell Death Detection Kit Roche (Mannheim, GER) 
MACS®  Pan T-Cell Isolation Kit II mouse Miltenyi Biotec GmbH (Bergisch Glad-
bach, GER) 
nCounter®  Mouse Immunology Kit NanoString Technologies (Seattle, USA) 
RevertAid First Strand cDNA Synthesis 
Kit 
Thermo Scientific (Waltham, USA) 
Peroxidase Substrate KIT DAB Vector (Burlingame, USA) 
QIAShredder Qiagen (Hilden, GER) 
RNeasy plus mini Kit Qiagen (Hilden, GER) 
Omniscript® RT Kit (200) Qiagen (Hilden, GER) 
Vectastain ABC Kit Vector (Burlingame, USA) 
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2.6 Antibodies 
2.6.1 Primary antibodies 
Table 6 I List of utilized primary antibodies, clone and their producer 
Primary Antibody Clone  Company 
   
α-SMA 1A4 Sigma-Aldrich (St. Louis, USA) 
Cleaved Caspase-3 D175  Cell Signaling (Danvers, USA) 
Collagen 1α1 polyclonal BioTrend (Köln, GER) 
Cyclin A polyclonal 
Santa Cruz Biotechnology (Dallas, 
USA) 
Desmin polyclonal R&D Systems (Minneapolis, USA) 
Glutamin synthetase (GS) polyclonal Abcam (Cambridge, UK) 
Ki-67 polyclonal  Leica (Wetzlar, GER) 
PCNA PC10 Dianova (Hamburg, GER) 
pRb  Cell Signaling (Danvers, USA) 
 
 
2.6.2 Secondary antibodies 
Table 7 I List of utilized secondary antibodies and their producer 
Secondary Antibody Company 
 
 
Goat anti-rabbit / Alexa 546 Invitrogen (Paisley, UK) 
Rabbit anti-goat / Alexa 488 Invitrogen (Paisley, UK) 
Goat anti-rat / Cy3® Invitrogen (Paisley, UK) 
Goat anti-mouse IgG-HRP Santa Cruz Biotechnology (Dallas, USA) 
Rabbit anti-goat IgG-HRP Santa Cruz Biotechnology (Dallas, USA) 
Anti-rabbit IgG-HRP Santa Cruz Biotechnology (Dallas, USA) 
Biotinylated anti-rabbit Vector (Burlingame, USA) 
Biotinylated anti-rat Vector (Burlingame, USA) 
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2.6.3 FACS-antibodies 
Table 8 I List of utilized FACS-antibodies, clone and their producer 
FACS - Antibody Clone Company 
   
CD2 / FITC RM2-5 eBioscience (Frankfurt, GER 
CD3e / APC 145-2C11 eBioscience (Frankfurt, GER) 
CD3e / BV510 145-2C11 BD (Franklin Lakes, USA) 
CD4 / PE GK1.5 eBioscience (Frankfurt, GER) 
CD4 / V450 RM4-5 BD (Franklin Lakes, USA) 
CD8 / FITC 53-6.7 eBioscience (Frankfurt, GER) 
CD11b / PE M1/70 eBioscience (Frankfurt, GER) 
CD11c /  APC N418 eBioscience (Frankfurt, GER) 
CD19 / Percp-Cy5.5 1D3 BD (Franklin Lakes, USA) 
CD25 / Percp-Cy5.5 PC61 BD (Franklin Lakes, USA) 
CD45 / APC-eFluor® 780 30-F11 eBioscience (Frankfurt, GER) 
CD152 (CTLA-4) / PE UC10-4B9 eBioscience (Frankfurt, GER) 
CD244.2 (2B4) / APC eBio244F4 eBioscience (Frankfurt, GER) 
FOXP3 / PE-Cy7 FJK-16s eBioscience (Frankfurt, GER) 
F4/80 / PE-Cy7 BM8 eBioscience (Frankfurt, GER) 
Gr1-Percp / Cy5.5 RB6-8C5 BD (Franklin Lakes, USA) 
Ly6G / FITC 1A8 BD (Franklin Lakes, USA) 
NK1.1 / PE-Cy7 PK136 eBioscience (Frankfurt, GER) 
PD1 / APC RMP1-30 eBioscience (Frankfurt, GER) 
Rorγt / PE Q31-378 BD (Franklin Lakes, USA) 
TIM3 / PE RMT3-23 eBioscience (Frankfurt, GER) 
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2.7 Buffers and Solutions 
Table 9 I List of buffers and solutions that were used for genotyping 
 
NID-Buffer (1 L): 
 
0,05 M 1M KCL 
0,01 M Tris / HCL pH8,3 
0,002 M 1M MgCl2 
0,1mg/ml Gelatine Type B  
0,45% ml NP40 
0,45% Tween-20 
 
Loading-Dye (100 ml): 
 
50 mg Bromphenolblue   
50 mg Xylenecyanole  
31ml Glycerol 
20 ml 0,5 M EDTA 
 
DNA-Ladder (100 µl): 
 
10 µl DNA Marker 1kbplus Ladder® 
10 µl Loading-Buffer 
80 µl Distilled water 
 
 
Table 10 I List of buffers and solutions that were used for histology 
 
Citric Acid Buffer pH 6.0 (1L): 
 
21 g Citric Acid Monohydrate 
 
PBT (50 ml): 
 
43,5 ml H2O 
5,0 ml 10x PBS  
0,5 ml 10 % BSA  
1,0 ml 10 % Triton X-100  
 
Sirius Red Solution pH 2,0 (250 ml):  
 
0,25 g Sirius Red 
250 ml Picric Acid (1,2 %) 
 
Blocking solution: 
 
20 % goat serum 
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0,3% Triton X-100 
Antibody solution:   
      
1 % BSA 
0,3 % Triton X-100 
 
2 % PBS-azide (50 ml): 
 
1 g Sodium azide 
 
 
Table 11 I List of buffers and solutions that were used for protein Isolation and Western Blot 
 
NP40 Buffer (500 ml) stock solution: 
 
 
 
 
NP40 Buffer: 
 
25 ml 1 M Tris HCL pH 7,5 
15 ml 5 M NaCl 
2,5 ml NP40 
1,05g NaF 
 
10 ml NP40 Buffer stock solution 
1 Complete Mini® tablet 
1 PhosStop tablet 
100 µl 0,1 M Pefablock 
10 µl 1 M DTT 
 
6x Laemmli Buffer (10 ml):                              
 
 
 
 
 
Buffer A (1L) pH 8,8: 
 
1,2 ml Tris 0,5 M pH 6,8 
4,7 ml Glycerol 
1,2 g SDS 
6 mg Bromophenol blue 
0,93 g DTT 
 
191,7 g Tris 
4g SDS 
 
Buffer B (1L) pH 6,8: 60,6 g Tris 
4 g SDS 
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Separating Gel (12,5 %): 14,32 ml Distilled water 
14,8 ml Buffer A 
20,87 ml Acrylamide 
300 µl Aps 
30 µl TEMED 
 
Stacking Gel: 
 
18 ml Distilled water 
7,5 ml Buffer B 
4,5 ml Acrylamide 
225 µl Aps 
15 µl TEMED 
 
10x Transfer Buffer (1L): 
 
 
Working solution: 
24,4 g Tris 
112,6 g Glycin 
 
100 ml 10x Transfer buffer 
200ml Methanol 
700 ml Distilled water 
 
TBS (1L): 
 
 
TBST: 
 
24,08 g Tris   
80 g  NaCl 
 
899 ml Distilled water 
100 ml TBS 
1 ml Tween-20 
 
 
Table 12 I List of buffers and solutions for FACS analysis 
 
FACS blocking-buffer (15ml): 
 
100 µl mouse serum 
100 µl rabbit serum 
100 µl human serum 
333 µl 30% BSA 
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PBS 
diluted 1:2 in HBSS + directly before use 
 
HBSS +: 
 
500 ml HBSS 
1ml 30% BSA 
1,5 ml EDTA 
 
 
2.8 Primer-Sequences 
All Primer were purchased from Eurofins MWG Operon (Huntsville, USA) 
 
2.8.1 Primer for genotyping 
Table 13 I List of utilized primer sequences for genotyping 
 Forward Reverse 
   
Cre CCACGACCAAGTGACAGCAAT TTCGGATCATCAGCTACACCA 
NEMO GCCTTGGTGCTCCCTAACTCT TATGTTTCACATCACATCGTTATCC 
Crem-α CCTCTACCATTCTTGCAATCAG GCAGGCGATGCAGCATCCTCATAATGG 
 
 
2.8.1 Primer for q-PCR   
Table 14 I List of utilized primer sequences for q-PCR   
 Forward Reverse 
   
AFP GAAGTGGATCACACCCGCTT TTTTCGTGCAATGCTTTGGA 
Bak GGTCTCTACGCAAATTCAGGG GTGACCTGCTTTTTGGCTGAT 
Bax CGAGCTGATCAGAACCATCA GGTCCCGAACTAGGAGAGGA 
Bcl-XL GCTGGGATGTTAGATCACTGAACG CCACAGCAGCAGTTTGGATGC 
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 Forward Reverse 
   
Bcl-2 ATGCCTTTGTGGAACTATATGGC GGTATGCACCCAGAGTGATGC 
Bim CCCGGAGATACGGATTGCAC GCCTCGCGGTAATCATTTGC 
CD2 AAGGCCCTCCTTTACCCAGA TCTTAATTAGGGGGCGGCAG 
CD25 CGCCAAGCATTCACCTAACG TTGGGCCCTCTCTCCCATTA 
c-myc AGCAACAACCGCAAGTGCT GTCCGCCTCTTGTCGTTTTC 
Crem-α AACTGTCCTCTGATGTGCCTGG TTGCCCCGTGCTAGTCTGATAT 
CTLA-4 ACTGAGAGCTGTTGACACGG AGAATCCGGGCATGGTTCTG 
GAPDH TGTTGAAGTCACAGGAGACAACCT AACCTGCCAAGTATGATGACAA 
IL-10 ACAATAACTGCACCCACTTC CCCAAGTAACCCTTAAAGTCC 
IL-17A TGAGCTTCCCAGATCACAGA TCCAGAAGGCCCTCAGACTA 
NEMO CTGGTGCAGAGACTGAGCTTGG TTCTCCCAGCAATGATGTCACC 
PCNA AAAATTGCTGACATGGGACAC CAGAAAAGACCTCAGGACACG 
RORγt CCGCTGAGAGGGCTTCAC CATGACTGAGAACTTGGCTCCC 
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3. Methods  
 
3.1 Animal experiments 
 
3.1.1 Knockout mouse strains 
 
The cre/loxP System is a recombination system that enables the tissue or cell type 
specific deletion of DNA sequences and thus the generation of conditional knockout 
organisms. Cre recombinases catalyze the disruption and recombination of DNA at 
specific DNA sequences, so called loxP sites. Depending on the chosen promoter the 
Cre activity is limited to certain cell types. In so called AlfpCre transgenic mice the 
Cre recombinase is controlled by the mouse albumin enhancer, promoter and the 
mouse alpha-fetoprotein enhancers. Therefore it is active in liver parenchymal cells, 
namely hepatocytes (66). In order to generate hepatocyte specific Nemo knockout 
mice (NemoΔhepa) C57BL/6 Nemof/f mice, in which exon 2 of the Nemo gene has been 
flanked by loxP sites (floxed), were crossed to C57BL/6 AlfpCre transgenic mice as 
described previously (67).  
CREMα transgene mice (CREMα mice) exhibit an overexpression of the CREMα 
gene, controlled by the CD2 promoter, for example in T-cells (68,69). 
C57BL/6 NemoΔhepa mice were crossed to CREMα FVB/N mice in order to generate 
NemoΔhepa / CREMα mice on a mixed background. The corresponding control 
animals (WT, NemoΔhepa and CREMα) were backcrossed from the same initial 
breeding couple. 
For age progression experiments 8, 13, 26 and 52 weeks old male mice were used.  
 
3.1.2 Animal housing 
 
Mice were housed in the Institute of Laboratory Animal Science at the University 
Hospital, RWTH-Aachen University, according to German legal requirements 
(Deutsches Tierschutzgesetz, FELASA, GV-SOLAS) under a permit of the 
Veterinäramt der Städteregion Aachen.  
Mice were kept in individual ventilated cages (IVC) in groups of max. 5 animals per 
cage under specific pathogen free (SPF) conditions. Air conditioning ensured a 
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constant room temperature of about +20 °C and humidity of 50-60%. By artificial light 
of 300 lux a 12 h light-dark cycle was assured. Animals received autoclaved food 
pellets and sterilized drinking water ad libitum. 
After separating the littermates at around 3 weeks of age, the animals received ear 
marks for identification and a tail biopsy for genotyping was taken. 
All organ explants and animal experiments were approved by the Landesamt für 
Natur, Umwelt und Verbraucherschutz NRW (Tierversuchsantrag 11135A4, 
10989A4, 10562A6, 10628G1). 
 
3.1.3 Blood withdrawal 
 
Before taking blood samples the mice were anesthetized with isoflurane. About 50 µl 
blood was taken by inserting a glass capillary into the medial canthus of the eye in 
order to puncture the orbital venous plexus. The emerging blood was collected into 
blood sample collection tubes. The serum was separated from the cellular 
compartment by centrifugation (10000 rpm, 5 min, RT). To assess the serum 
parameters aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (AP) and glutamate dehydrogenase (GLDH) the serum was 
diluted 1:10 in PBS. The measurement has been performed by the clinical routine 
laboratory of the University Hospital RWTH Aachen. 
 
3.1.4 Organ explant 
 
In order to explant the liver, mice were sacrificed by cervical dislocation under 
isoflurane anesthesia. After measuring the mice’s body-weight, the abdomen was 
opened along the linea alba and the liver was removed and weighted. To remove the 
blood the liver was then washed in cold PBS. Subsequently a picture of the liver was 
taken and the size of the liver and, as may be the case, the size and the number of 
tumors was measured via Diskus software from Carl H. Hilgers. 
Finally, the liver tissue was minced into small pieces and samples for different 
analysis were collected. For RNA and protein isolation some pieces were snap frozen 
in liquid nitrogen and stored at -80 °C. Two pieces each were fixed in PFA for 
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immunohistochemistry (IHC) or embedded into Tissue-Tek® for immunofluorescence 
staining (IF). Another piece was weighted and subjected to Flow cytometry (FACS). 
 
3.1.5 Bone marrow transplantation (BMT) 
 
To prove the role of Bone marrow derived cells (BMDCs) in my model I created bone 
marrow chimeric mice. Additionally, these mice received a boost-injection of T-cells 
to intensify the effect of these cells. 
6- 10 weeks old donor mice were sacrificed by cervical dislocation under isoflurane 
anesthesia. Femur and Tibia were dissected from the hind legs and cleaned from 
adherent tissue. In order to collect the BMDCs the joint heads were broken off. By 
flushing the bone with HBSS, containing 1% FCS the cells were collected into a 50 
ml centrifugation tube. After a washing step with HBSS, the cells were counted and 
adjusted to a final concentration of 106 BMDCs / 100 µl HBSS + 1 % FCS. 
T-cells were isolated from the spleen using MACS® technique as described below 
and adjusted to a final concentration of 106 T-cells / 100 µl HBSS + 1 % FCS. 
 
6 week-old recipient mice were lethally irradiated. Within the framework of 3 h the 
mice received a dosage of 2 x 6.8 Gy. Next, 106 BMDCs and 106 T-cells were 
merged and a final volume of 200 µl was administered to the recipient mice via tail 
vein injection. To prevent early death due to infections, the mice received antibiotic 
treatment for 2 weeks. Therefore 40 µl Borgal-solution (24%) were added per 100 ml 
drinking water. The mice were sacrificed 8 weeks after BMT. 
 
3.2 Genotyping 
 
3.2.1 DNA-isolation using NID-buffer 
 
To assess the genotype of the mice a 1-2 mm big tail biopsy (tip of the tail) was 
taken. To isolate the DNA, the tails were lysed at 56°C in 200 µl NID-Buffer + 1 µl 
Proteinase K overnight. In order to deactivate Proteinase K activity the lysate was 
boiled for 15 min at 95°C. 
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3.2.2 PCR 
 
Table 15 I Composition of genotyping-PCR (for one sample): 
Reagent Cre Nemo Crem-α 
    
H20 8,5 µl 9,5 µl 9,5 µl 
Primer 1 1 µl Cre4 1 µl M27 1 µl Crem-α1 
Primer 2 1 µl Cre5 1 µl Lox-SCR1 1 µl Crem-α2 
Red Taq 12,5 µl - - 
Hot Start Taq - 12,5 µl 12,5 µl 
Mix 23 µl 24 µl 24 µl 
DNA 2 µl 1 µl 1 µl 
 
 
Table 16 I PCR program Cre. The PCR-Reaction for Cre yields a 300-400 Kb fragment.  
Phase Temperature Time Cycles 
    
Initial Denaturation 95°C 5 min 1 
Denaturation 94°C 15 sec 
35 Annealing 54°C 30 sec 
Elongation 72°C 30 sec 
Final Elongation 72°C 5 min 1 
 
 
Table 17 I PCR program Nemo. The PCR-Reaction for Nemo yields a WT-Band at 450 Kb and a 
Knockout-Band at 500 Kb. 
Phase Temperature Time Cycles 
    
Initial Denaturation 98°C 15 min 1 
Denaturation 98°C 15 sec 
40 Annealing 55°C 30 sec 
Elongation 72°C 40 sec 
Final Elongation 72°C 10 min 1 
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Table 18 I PCR program Cremα. The PCR-Reaction for Cremα yields a 650 Kb fragment.  
Phase Temperature Time Cycles 
    
Initial Denaturation 98°C 15 min 1 
Denaturation 98°C 15 sec 
40 Annealing 55°C 30 sec 
Elongation 72°C 40 sec 
Final Elongation 72°C 10 min 1 
 
 
3.2.3 Gel electrophoresis 
 
To visualize PCR products, they were ordered by size using Gel electrophoresis and 
stained with Ethidiumbromide (EtBr). Therefore a 1-2% agarose gel was poured, by 
boiling the required amount in TAE-Buffer and one-two drops EtBr were added. EtBr 
is a dye which intercalates nucleic acids and fluoresces when it is exposed to UV 
light. 4 µl Loading-Dye were added to the products of the Nemo and Cremα PCR. For 
the Cre PCR pre-stained Redtaq® was used. After loading the samples on the gel, 
170 V for 45 min in an electrophoresis chamber filled with TAE-Buffer, were applied. 
Finally, the bands could be visualized using an UV-transilluminator. To determine the 
size of the PCR products a DNA-Ladder was loaded to the gel. 
 
3.3 RNA 
 
3.3.1 RNA-Isolation from liver tissue 
 
To isolate the RNA a cryopreserved piece of liver tissue, sized like a grain of 
rice, was homogenized in 1 ml peqGOLD RNAPure, using an Ultra-Turrax. peqGOLD 
RNAPure lyses the cells, deactivates enzymes like RNAses and solubilizes the RNA. 
After 5 min incubation at room temperature (RT), 200 µl chloroform were added to 
separate the phases. The liquids were vortexed for 15 sec followed by 10 min 
incubation at RT and 5 min centrifugation at 12000 x g. The aqueous (upper) phase, 
containing the RNA, was removed and transferred into a new 1,5 ml collecting tube. 
Afterwards 500 µl isopropanol were added and the tube was gently mixed to 
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precipitate the RNA. After 15 min incubation at RT the RNA was pelleted by 10 min 
centrifugation at 12000 x g and 4°C. The RNA pellet was washed twice using freshly 
prepared 70 % ethanol. After removing the ethanol the pellet was air dried for 15 min 
and dissolved, depending on the pellet size, in 60-100 µl DEPC treated water. The 
RNA was snap frozen in liquid nitrogen and stored at -80 °C. 
 
3.3.2 Determination of the nucleic acid concentration 
 
To assess the Nucleic Acid concentration the RNA was diluted 1:50 in DEPC-treated 
water. The optical density at 260 nm (OD260) was measured in a spectral photometer. 
Additionally the OD280 was measured and the samples were blanked against DEPC-
treated water. To calculate the RNA concentration the following formula was used: 
 
μ
μ
= 	
	260				
1000
 
 
F: absolute term for RNA  
D: Dilution factor  
 
The purity of the isolated RNA, or the contamination with proteins, can be assessed 
by the relation between OD260 and OD280.  
OD260
OD280
	 
A protein free nucleic acid solution typically has a relationship of 1,8 – 2,0. 
 
3.3.3 cDNA synthesis 
 
To transcribe the isolated RNA into cDNA the Omniscipt® RT Kit (200) was used.  
For transcription 2 µg total RNA were used and diluted in DEPC water to a total 
volume of 12,5 µl. Afterwards 7,5 µl of the reaction mix were added to each sample. 
 
Reaction Mix (per sample):  2 µl Buffer 
     2 µl dNTPs 
     2,5 µl Oligo dT Primer 
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     1 µl Reverse Transcriptase 
 
The complete mixture was incubated at 37°C for 1 h. After hybridization the cDNA 
was diluted 1:20 in DEPC- treated water and stored at -20 °C. 
 
3.3.4 Real-Time quantitative PCR (q-PCR) 
 
The q-PCR enables the amplification of DNA and the Quantification of the relative 
amount of DNA products. For this approach SYBR® Green was used, a dye that 
randomly binds to double stranded DNA. This binding in turn increases its 
fluorescence activity. The reaction mix was as follows. 
 
Reaction mix (per sample): 6,5 µl DEPC- treated water 
     0,5 µl Primer forward 
     0,5 µl Primer reverse 
     12,5 µl SYBR® Green 
     5 µl cDNA 
 
 The q-PCR reaction was measured in duplicates for all samples.  
 
Table 19 I Program for q-PCR   
Phase Temperature Time Cycles 
    
Activation 50 °C 2 min  
Initial Denaturation 95 °C 10 min  
Denaturation 95 °C 15 sec 
40 
Annealing / Elongation 60 °C 1 min 
 
To analyze the results of the q-PCR so called cycle of threshold (Ct) values were 
derived using AB 7300 System SDS Software. Thereby the Ct value denotes the 
cycle in which the fluorescence signal is clearly detectable and therefore higher than 
the noise. Accordingly, the lower the Ct value the earlier the signal is detected and 
therefore, the higher is the original number of copies of the target gene. The mRNA 
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expression was calculated using the 2−∆∆CT Method (70) correlating with the 
expression of the target gene dependent on reference gene expression (GAPDH). 
 
3.4 Proteins 
 
3.4.1 Protein isolation 
 
Liver proteins were isolated from frozen tissue and homogenized in 500 µl NP40 
buffer. Then the cellular component was pelleted by centrifugation at 12.000 rpm and 
4°C for 10 min. The supernatant was snap frozen in liquid nitrogen and stored at -80 
°C until use. 
 
3.4.2 Bradford assay 
 
To assess the protein concentration the BIO-RAD Protein Assay was used. This 
reagent is based on the method described by Bradford (71) which describes that the 
absorption peak of Coomassie Brilliant Blue G-250 is shifted from 465 nm to 595 nm 
upon protein binding. For the assay 2 µl of each sample were mixed with 998 µl BIO-
RAD protein reagent, which had been diluted 1:5 in distilled water. As blank 2 µl 
NP40 Buffer were used. To generate a standard curve BSA standards of 1 mg/ml, 
2,5mg/ml, 5 mg/ml, 7,5 mg/ml, 10 mg/ml, and 15 mg/ml were diluted in BIO-RAD 
Protein reagent in the same way as described for the samples. The OD595 was 
measured in a spectral photometer. To determine the protein concentration, the 
OD595 of the samples was compared with a standard curve, which has been derived 
from the BSA standards.  
Finally, the proteins were adjusted to a final concentration of 2 µg/µl using NP40-
Buffer and Laemmli-Buffer. 
 
3.4.3 Western Blot 
 
First of all the proteins had to be denaturized in order to break down the secondary 
and tertiary structure. Therefore the proteins were incubated for 5 min at 95 °C in a 
denaturizing buffer.  
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To separate the proteins by their molecular weight a SDS gel, consisting of a 
stacking and 12,5 % separating gel was poured. The gel was placed into an 
electrophoresis chamber, filled with running buffer, and 60 µg of the protein were 
loaded into the wells. To determine the size of the proteins 10 µl Novex® Sharp Pre-
stained Protein Standard were loaded into the first well of the gel. A voltage of 70 V 
was applied overnight. For detection of the proteins by antibodies they were 
transferred onto a nitrocellulose membrane. Therefore, a piece of membrane and the 
gel were placed between 2 Whatman® papers and placed into a blotting chamber, 
which was filled with transfer buffer. 65 V were applied for 2.15 h. To prove the 
successful transfer a Ponceau red staining was performed. After washing the 
membrane in TBST it was blocked 1 hour by incubation in 5% BSA. To detect our 
protein of interest, the membrane was incubated in primary antibody (1:1000 diluted 
in 5% BSA) at 4°C overnight. After washing with TBST, the membrane was incubated 
for 1 hour at RT in secondary, HRP labeled antibody (1:5000 in 5% BSA). The blot 
was developed using ECL Prime Western Blotting Detection Reagent and the signal 
was visualized using a Luminescent Image Analyzer (FUJIFILM). 
 
3.5 Histology 
 
3.5.1 Immunofluorescence staining 
 
Liver tissue of mice was embedded into Tissue-Tek® and deeply frozen. Cryoblocks 
were cut into 5 µm sections and attached to an object slide. The slides were stored at 
-20 °C. 
 
3.5.1.1 Ki-67 
 
Fresh slides were fixed in 4 % PFA for 10 min followed by three repetitive washing 
steps, each 10 min, in PBS. To avoid unspecific antibody-binding the liver sections 
were incubated for 1 h at RT with 100 µl blocking solution. 
The blocking solution was removed by 3x repeated washing step for 5 min using 
PBS. Afterwards 50 µl of the primary anti-Ki-67 antibody were incubated (1:500 in 
antibody solution) overnight.   
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Then the slides were washed 3 x 5 min in PBS. 50 µl goat anti-rabbit antibody 
labeled with Alexa 546 fluorescent dye were incubated for 1 h at RT (1:1000 in 
antibody solution).Finally the slides were washed 3 x 5 min in PBS and mounted with 
a DAPI containing mounting medium.  
Pictures were taken using AxioVision© software. The number of positive cells was 
assessed via ImageJ. 
 
3.5.1.2 Desmin / Collagen  
 
Slides were thawed and then fixed in 4 % PFA for 10 min followed by 3x repeated 
washing step, each 3 min, in PBS-azide (10ml 2 % PBS-azide / 1L PBS). 
To avoid unspecific antibody-binding the liver sections were incubated for 10 min at 
RT with PBS-azide containing 0,2 % BSA. Next, 50 µl of the primary anti-Collagen / 
Desmin antibody were applied (1:200 in PBS-azide containing 1 % mouse serum) for 
45 min at RT. Afterwards the slides were washed 3 x 5 min in PBS-azide. 50 µl of the 
corresponding secondary antibody (Collagen: goat anti-rabbit labeled with Alexa 546; 
Desmin: rabbit anti-goat labeled with Alexa 488) were incubated for 45 min at RT 
(1:300 in in PBS-azide containing 1 % mouse serum). Finally the slides were washed 
3 x 5 min in PBS-azide followed by 3 x 5 min in distilled water and mounted with a 
DAPI containing mounting medium. 
Pictures were taken using AxioVision© software. The positive area fraction was 
quantified via ImageJ. 
 
3.5.2 Immunohistochemistry 
 
Pieces of murine liver tissue were fixed in 4% PFA and embedded into paraffin. All 
immunohistochemical stainings were performed with paraffin section. 
 
3.5.2.1 Hematoxylin & Eosin staining (H&E) 
 
The H&E staining method is the most widely used staining technique in medical 
diagnosis and visualizes the structure of the stained tissue. It is commonly used to 
get a general overview about the morphology of a tissue and / or pathological 
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changes, such as tumor growth. Hemalum, a hematoxylin derivate, stains all basophil 
structures, especially the nuclei and the rough endoplasmic reticulum in blue. Eosin 
is an acetic dye that stains eosinophilic structures, like most of the cytoplasm, in red. 
The H&E staining was performed by the Institute of Pathology of the University 
Hospital, RWTH-Aachen. The staining was evaluated by Prof. Dr. med. Thomas 
Longerich from the Institute of Pathology, University Hospital, RWTH Aachen.  
 
3.5.2.2 Sirius red 
 
The Sirius red staining is a commonly used method to stain collagen fibers. Once  
exposed to polarized light the fibers emerge orange (Collagen I) or green (Collagen  
III) on a dark background. 
The slides were dewaxed by incubation for 15 min at 65 °C followed by 2 x 5 min 
incubation in xylene. Then they were rehydrated using a descending ethanol series 
(2 x 100%, 2 x 95%, 1x 90%, 1 x 80%, 1 x 70%, 1 x distilled water). Afterwards the 
slides were incubated for 45 min in a 0,1% Sirius Red solution. The staining was 
fixed by 2 x 15 sec incubation in 0,5% glacial acetic acid. To remove the water from 
the tissue the slides were dehydrated in an ascending ethanol series (1 x 95%, 2x 
100%), cleared in xylene and mounted using Roti®-Histokitt. 
Pictures were taken using AxioVision© software. The positive area fraction was 
quantified via ImageJ. 
 
3.5.2.3 Cleaved Caspase-3 / Glutamine synthetase / α-SMA 
 
The slides were dewaxed by incubation for 15 min at 65°C followed by 2 x 2 min 
incubation in xylene. Afterwards they were rehydrated using a descending ethanol 
series (2 x 100%, once 95%, 90%, 80%, 70%, distilled water). 
To restore the immunoreactivity of the tissue the slides were subjected to antigen 
retrieval. Therefore the slides were boiled for 10 min in 10 mM citric acid buffer. 
After 15 min of cooling, the remaining buffer was removed by washing the slides 5 
min in tap water. This was followed by 15 min 2,5% H2O2 to block endogenous 
peroxidase activity and another washing step of 5 min. Afterwards all endogenous 
biotin, biotin receptors and avidin binding sites had to be blocked, using the avidin / 
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biotin blocking kit. Therefore they were incubated 15 min at RT in avidin, followed by 
another 15 min blocking at RT with biotin. To block unspecific binding sites slides 
were further incubated for 30 min at RT in 50% FCS + 50% PBS containing 1% BSA. 
Slides were then incubated overnight at 4°C in the primary antibody (1:1000 in PBT). 
To remove excess primary antibody, the slides were washed twice for 5 min in PBS 
and further incubated for 1 h with a secondary, biotinylated anti-rabbit antibody at RT. 
Subsequently slides were washed and treated with a preformed Avidin/Biotinylated 
enzyme complex (Vectastain ABC Kit) for 1h at RT. Finally the staining was 
developed by adding the enzyme substrate 3,3'-diaminobenzidine (DAB peroxidase 
(HRP) substrate kit). The reaction was stopped by rinsing with Distilled water. To 
visualize the cellular structure, slides were counterstained according to 
manufacturer’s instructions using Mayer's acid hemalum. Briefly, slides were 
immersed in Mayer's acid hemalum for 10 min and blued by rinsing slides in running 
tap water for 15 min. 
To remove the remaining water from the tissue the slides were dehydrated in an 
ascending ethanol series (1 x 95%, 2 x 100%), cleared in xylene and mounted using 
Roti®-Histokitt. 
Pictures were taken using AxioVision© software. The number of positive cells was 
assessed via ImageJ. 
 
3.6 Leukocyte isolation from different organs  
 
3.6.1 Liver 
 
After the mouse was sacrificed, blood leukocytes were removed from liver tissue by 
perfusing the liver with PBS. A 0,1 – 0,4 mg piece of liver was incubated for 45 min in 
5 ml RPMI Medium + 2 mg Collagenase Type 2 at 37°C on a shaker to digest the 
liver tissue. Afterwards the liver was minced through a 70 µm cell strainer, using the 
plunger of a 5 ml syringe, into a 50 ml centrifugation tube and 10 ml HBSS + were 
added.  
The sample was centrifuged for 5 min at 500 rpm to separate leukocytes from 
hepatocytes, which sediment under these conditions due to their density. By 
centrifugation of the supernatant for 10 min at 1500 rpm leukocytes were pelleted. 
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After wasting the supernatant the remaining erythrocytes were lysed. This was done 
by a 15 min Incubation with BD Pharm Lyse™ (diluted 1:10 with distilled water, 5 ml 
per sample) at 4°C. Lysis was stopped by adding 10 ml PBS. Cells were pelleted by 
centrifugation, resuspended in PBS and stored at 4°C until further use. 
 
3.6.2 Spleen 
 
The spleen was squashed through a 70 µm cell strainer, using the plunger of a 5 ml 
syringe. Cells were pelleted by centrifugation at 1500rpm for 10 min at 4°C and 
resuspended in BD Pharm Lyse™ to remove remaining erythrocytes. After 15 min of 
incubation at RT lysis was stopped by adding 10 ml PBS. The cells were pelleted by 
centrifugation, resuspended in HBSS + and stored at 4°C until further use. 
 
3.6.3 Blood 
 
To prevent clotting the blood was mixed1:2 with HBSS+. The cells were pelleted by 
centrifugation at 1500rpm for 10 min at 4°C and resuspended in BD Pharm Lyse™ to 
remove remaining erythrocytes. After 15 min of incubation at RT lysis was stopped by 
adding 10 ml PBS. The cells were pelleted by centrifugation, resuspended in HBSS + 
and stored at 4°C until further use. 
 
3.7 Fluorescent activated cell sorting (FACS) 
 
3.7.1 Staining of cell surface marker 
 
The cells were split into two FACS-Tubes and pelleted by centrifugation (1500 rpm, 
10 min, 4 °C). The antibodies against Ly6G, CD11b, CD11c, F4/80, Gr1 and CD45 or 
CD8, CD4, CD3, NK1.1, CD19 and CD45 respectively were diluted 1:400 in blocking 
Buffer. 20 µl of the antibody mix were added per sample and incubated for 15 min at 
4C°.  Afterwards excess antibody was removed by washing with 1x PBS. Finally, the 
cells were diluted in 200 µl HBSS +. Shortly before the measurement 15 µl Hoechst, 
to identify dead cells, as well as approximately 12.000 APC-Calibrate-Beads, to 
determine the total cell number, were added. Alternatively, the cells were stained with 
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antibodies against CD3, CD4, CD8, CD25, CTLA-4, PD-1 and CD45 or CD3, CD4, 
CD8, CD25, TIM3, 2B4 and CD45 respectively and subjected to intracellular staining 
of transcription factors. 
 
3.7.2 Staining of transcription factors 
 
To allow antibody binding to intracellular proteins the cells were permeabilized using 
the FOXP3 staining buffer set. Therefore leukocytes cells were vortexed in 500 µl 
fixation / permeabilization solution and incubated in the dark for 30 min at 4 °C. To 
remove the fixation / permeabilization solution the cells were washed using 2 ml perm 
buffer and subjected to intracellular staining. Therefore the antibodies against FOXP3 
and CTLA-4 or FOXP3 respectively were diluted 1:200 in perm buffer. 20 µl of the 
antibody mix were added per sample and incubated for 30 min at 4°C. Excess 
antibody was removed by washing with 2 ml perm buffer. Finally the cells were 
resuspended in 200 µl HBSS +. 
Data were analyzed using FlowJoTM Version 7.5 software.  
 
3.8 Magnetic cell isolation 
 
T-Cells were isolated using Magnetic Cell Isolation (MACS) technique. With this 
method cell populations are labeled using specific antibodies coupled to magnetic 
beads and bound to a magnetic column, while unlabeled cells pass through. By 
rinsing the column, outside of the magnetic field, the labeled population can be 
eluted. If the labeled population is the target population, this process is called positive 
selection. However, if the unlabeled population is the population of interest it is then 
called negative selection. 
For this study the MACS® Pan T-cell Isolation Kit II mouse was used, according to 
manufacturers’ instructions. This kit sorts the T-cells via negative selection. Isolated 
T-cells were pelleted and stored in RNAprotect at -80 °C. Isolation was performed by 
Dr. rer. nat Kim Ohl from the Department of Pediatrics, University Hospital, RWTH 
Aachen.  
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3.8.1 RNA isolation from T-Cells 
 
RNA from MACS isolated T-cells was isolated using the RNeasy plus mini Kit due to 
manufacturers’ instructions. The homogenization step was performed using 
QIAShredder columns. The RNA concentration was determined by a NanoDrop 
Spectrophotometer.  
 
3.8.2 cDNA synthesis 
 
To generate cDNA from the isolated RNA the RevertAid First Strand cDNA Synthesis 
kit was used due to manufacturers’ instructions.  
In short, 100 ng total RNA were used and diluted in RNase free water to a total 
volume of 11 µl. 9 µl of the reaction mix were added to each sample. 
Reaction Mix (per sample):    
     4 µl Reaction-Buffer 
     2 µl dNTP Mix 
     1 µl Oligo(dT)18 Primer 
     1 µl RevertAid Reverse Transcriptase 
     1 µl Ribolock RNase Inhibitor 
 
The complete mixture was incubated at 37°C for 1 h. After hybridization the cDNA 
was diluted 1:5 in DEPC- treated water and stored at -20 °C. 
 
3.9 nCounter® Analysis System (nanostring) 
 
The nCounter® Analysis System is a new method to quantify the expression of up to 
800 genes simultaneously. Therefore, a mixture of barcode labeled, target specific 
capture probes is hybridized to the individual nucleic acid molecules.  
After immobilization of the labeled RNAs onto a cartridge, via a Biotin / Streptavidin 
system, the cartridge can be subjected to a specific reader, which is able to scan the 
barcodes and thus to count the single RNA molecules. For some approaches the 
company offers prebuild, ready to go sets, which contain a specific set of capture 
probes.  
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For this study the nCounter® Mouse Immunology Kit has been used. This kit enabled 
us to assess the expression pattern of 561 immunology related genes in mice. 
For the assay 80 ng total RNA, purified from MACS isolated T-cells, were diluted to a 
final volume of 5 µl using RNase free water. The samples were then hybridized with a 
mixture of the capture and the reporter probes at 65°C for about 16 h following 
manufacturers’ instructions. Samples were automatically immobilized onto a cartridge 
and aligned using the nCounter® Prep Station. 
The cartridge was read out at the West-German Lung Center, University Hospital 
Essen. 
Using the nSolver™ Analysis Software 2.0 the data were normalized to the DNA-
directed RNA polymerase II subunit RPB1 (Polr2a), a housekeeping gene, which 
showed the most consistent number of counts among the four different genotypes. 
The limma p-value was calculated by Dr. Mark V. Bokschoeten from the Institute for 
Nutrition, Metabolism & Genomics at the Wageningen University & Research Centre, 
Netherlands. 
Finally, data were subjected to pathway analysis using Ingenuity software (NIH, 
Bethesda) and the pathways of interest were calculated and represented by this 
software. 
To visualize the expression of genes related to the inhibitory profile of T-cells the fold 
induction was normalized to a range from -1.5 – 1.5 and represented using 
MultiExperiment Viewer software (MeV). The hierarchical gene clustering was 
obtained by Pearson Test Correlation (FC<1.5), (Red: up-regulated; Green: down-
regulated). This analysis was performed by Dr. rer. nat. Francisco Javier Cubero. 
 
3.10 Statistics 
 
Data were analyzed using Graph Pad Prism® 5.0 and are expressed as mean ± 
standard deviation (SD). As we were mainly interested in the differences between 
Nemo
∆hepa
 and Nemo
∆hepa/CREMα mice only these two groups were compared to 
each other. Using a Kolmogorov-Smirnov Test data were tested for Gaussian 
distribution and using a F-test variances were compared. If data were Gaussian 
distributed and owed equal variances a two-tailed unpaired Student t-test was 
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performed. If the variances were different two-tailed unpaired Student t-test followed 
by Welsh’s correction was performed. If data were not Gaussian distributed a Mann-
Whitney test was performed. Differences were considered significant when p-values 
were below 0.05. If other groups were compared with each other it is displayed in the 
figure legend. 
Outliers were defined using the definition of John W. Tukey: The Interquartile Range 
(IQR) is defined as Q3-Q1. Outliers are defined as values below Q1-1.5 IQR or above 
Q3+1.5 IQR. Thereby Q1 is the first quartile, the value in the data set that holds 25% 
of the values below it. Q3 is the third quartile, the value in the data set that holds 25% 
of the values above it. 
 
3.11 Software 
 
AB 7300 System SDS Software 
AxioVision©  
Diskus  
FlowJoTM Version 7.5  
Graph Pad Prism® 5.0 
ImageJ (NIH)  
Ingenuity software (NIH, Bethesda)  
MultiExperiment Viewer  
nSolver™ Analysis Software 2.0 
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4. Results 
 
4.1 Expression of IKKγ/nemo and cremα  
 
To investigate the impact of the CREMα transgene and the consequent TH17 
phenotype on CLD, I crossed CREMα transgene mice to Nemo∆hepa mice, a murine 
model of chronic liver injury. First of all, the correct breeding was confirmed by 
analyzing the gene expression for Nemo and Cremα (Figure 5).  
 
 
 
 
 
 
Therefore, mRNA from liver tissue or hepatic T-cells, respectively, was isolated. As 
shown, Nemo was efficiently deleted in the liver, since only a minor gene expression 
was detectable in Nemo
∆hepa
 and Nemo
∆hepa
/CREMα mice when compared with WT 
and CREMα mice (Figure 5A). T-cells, isolated from CREMα mice, displayed 
increased Cremα expression, although this difference was not significant compared 
with WT mice (Figure 5B). However, the Cremα mRNA expression was reduced in 
hepatic T-cells isolated from Nemo
∆hepa
/CREMα mice. 
Figure 5 I Knockout respectively transgene expression  
q-PCR for A) Nemo from liver tissue (WT vs. Nemo∆hepa). Data are shown as Box-Whisker Plot of 
n=4-6 mice per group (***p< 0.001) 
B) Cremα from hepatic T-cells (WT vs. CREMα, CREMα vs. Nemo∆hepa/CREMα). Data are shown 
as Box-Whisker Plot of n=4-5 mice per group. 
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4.2 Effect of CREMα on the onset of CLD in Nemo∆hepa mice 
 
Already at an age of 8 weeks Nemo∆hepa mice show signs of liver injury such as 
increased liver transaminases and a disturbance of liver histology (21). 
Transaminases are enzymes, which in healthy conditions are present in the 
cytoplasm of hepatocytes. Upon hepatocyte damage they are released into the 
blood. Thus, elevated serum concentrations of liver transaminases such as alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) are direct indicators of 
hepatic injury (72). In order to assess the degree of liver injury in 8 week-old 
Nemo
∆hepa 
vs. Nemo
∆hepa
/CREMα mice, serum AST (data not shown) and ALT values 
were measured and compared with healthy control mice. Although H&E staining of 
the liver revealed no major differences between Nemo
∆hepa 
and Nemo
∆hepa
/CREMα 
mice (Figure 6A), ALT values were significantly reduced in Nemo
∆hepa
/CREMα (Figure 
6B) – indicating less severe liver injury. 
 
 
 
Figure 6 I Determination of liver injury in 8 week-old mice 
A) Microscopical picture of H&E staining (scale bar: 200 µm) B) Serum alanine aminotransferase 
(ALT) levels (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=21-28 mice per 
group (*p< 0.05) 
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Figure 7 I Proliferation and apoptosis rate in 8 week-old mice 
A) Immunohistochemical staining for cleaved caspase-3 (scale bar: 200 µm) B) Immunofluorescence 
staining for Ki-67 (red: Ki-67, blue: DAPI, scale bar: 200 µm). C) Quantification of cleaved caspase-3-
positive cells (WT vs. CREMα, Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of 
n=5-8 mice per group. D) Quantification of Ki-67-positive cells (Nemo∆hepa vs. Nemo∆hepa/CREMα). 
Data are shown as mean ± SD of n=5-8 mice per group. E) q-PCR for the apoptosis related genes 
Bax, Bak, Bim, Bcl-2, Bcl-xl and for the proliferation marker Pcna (Nemo∆hepa vs. Nemo∆hepa/CREMα). 
Data are shown as mean ± SD of n=3-7 mice per group (*p< 0.05). 
 
4.2. CREMα transgene expression does not influence proliferation and 
apoptosis 
 
The phenotype, observed in Nemo
∆hepa
 mice, is strongly associated with the induction 
of hepatocyte apoptosis in these animals (21,26). Thereby, Caspases play an 
important role in the execution phase of cell apoptosis and can be used as markers 
for apoptosis. Thus, the number of apoptotic cells was assessed by 
immunohistochemical staining for the active form of caspase-3, named cleaved 
caspase-3 (Figure 7A). The quantification revealed no significant differences in the 
number of apoptotic cells in Nemo
∆hepa/CREMα compared with Nemo∆hepa mice 
(Figure 7C). This finding was further supported by gene expression analysis of the 
pro-apoptotic genes Bax, Bak and Bim and the anti-apoptotic genes, Bcl-2, Bcl-xl 
(Figure 7E).  
Because the liver is the only internal organ which is highly capable of regeneration, 
the hepatic parenchyma consequently responds to hepatocyte apoptosis with 
compensatory proliferation. Ki-67 is a marker for proliferation as it is present in all 
active phases of the cell cycle, while absent in resting cells (73). Thus an 
immunofluorescence staining for Ki-67 was performed (Figure 7B). 8 week-old 
Nemo
∆hepa 
mice showed a strong increase in proliferating and thus Ki-67 positive cells 
(Figure 7D), as published (21). The quantification of Ki-67 positive cells revealed no 
significant difference in Nemo∆hepa compared with Nemo∆hepa/CREMα mice. However, 
the gene expression of Pcna, a specific marker for the S-phase of the cell cycle (74), 
was significantly decreased in Nemo∆hepa/CREMα compared with Nemo∆hepa mice  
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(Figure 7E). 
 
4.2.2 CREMα improves fibrosis development in Nemo∆hepa mice 
 
An integral part of the wound healing response in the injured liver is the formation of 
fibrotic scars. This scar-tissue is built throughout the liver and consists of connective 
tissue, and major collagen type IA1 deposition.  
 
 
Figure 8 I Extracellular matrix deposition in 13 week-old mice 
A) Immunofluorescence staining for Collagen IA1 (yellow: Collagen IA1, blue: DAPI, scale bar: 200 
µm). B) Immunohistochemical staining for Sirius red (scale bar: 200 µm). C) Quantification of collagen-
positive area (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=6-11 mice per 
group (**p< 0.01). D) Quantification of Sirius red-positive area (Nemo∆hepa vs. Nemo∆hepa/CREMα). 
Data are shown as mean ± SD of n=6-11 mice per group (***p< 0.001). 
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Figure 9 I Activation of hepatic stellate cells (HSCs) in 13 week-old mice 
A) Immunofluorescence staining for Desmin (red: Desmin, blue: DAPI, scale bar: 200 µm). B) 
Immunohistochemical staining for α-SMA (scale bar: 200 µm). C) Quantification of Desmin-positive 
area (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=6-11 mice per group 
(**p< 0.01).  
 
It has already been shown that Nemo
∆hepa mice develop severe fibrosis as a result of 
CLD within a lifetime of 13 weeks (21).  
Therefore, the degree of extracellular matrix deposition was investigated by 
immunofluorescence staining for Collagen IA1 as a marker for CLD progression 
(Figure 8A). The quantification of the Collagen IA1 positive area revealed a 
significant reduction in Collagen IA1 deposition in Nemo∆hepa/CREMα compared with 
Nemo
∆hepa 
mice (Figure 8B). Another method to determine the degree of scarring is 
Sirius red staining. This method is not only valid to determine the amount of Collagen 
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IA1, but also of Collagen III. In order to confirm the results of the Collagen IA1 
staining, an immunohistochemical staining for Sirius red was performed. In line with 
previous data, also the amount of Sirius red positive fibers was reduced in 
Nemo
∆hepa/CREMα compared with Nemo∆hepa mice, thereby indicating reduced scar 
formation in these mice.  
The main producers of extracellular matrix in the liver are HSCs (6). In a quiescent 
state HSCs are responsible for Vitamin A storage. Upon liver injury they become 
activated and transform into Collagen producing myofibroblasts. Desmin and α-SMA 
are two commonly used markers for HSCs activation. To investigate whether a 
decreased number of HSCs was responsible for reduced Collagen deposition in 
Nemo
∆hepa/CREMα mice, an immunofluorescence staining for Desmin (Figure 9A), as 
well as an immunohistochemical staining for α-SMA (Figure 9B), were conducted. 
The quantification of the Desmin positive area revealed a significant reduction in 
Nemo
∆hepa/CREMα compared with Nemo∆hepa mice (Figure 9C), suggesting a 
reduction in the number of HSCs.  
 
4.2.3 Immune cell infiltration 
 
Liver injury is usually accompanied by an inflammatory response of the liver – called 
hepatitis. Damaged hepatocytes release soluble chemo attractants in order to attract 
phagocytes. They further express danger associated molecular patterns (DAMPs) on 
their cell surface which can be nuclear or cytosolic proteins, purine metabolites or 
RNA and DNA molecules. The presence of these mediators, outside of cells, signals 
tissue injury, targets the cells for phagocytosis and initiates a noninfectious 
inflammatory response (75). Activated immune cells further secrete cytokines and 
chemokines to induce a wound healing response as they can induce hepatocyte 
proliferation and scar formation (76,77). However, if the cause of liver injury persists, 
like in Nemo
∆hepa 
mice, a chronic inflammation develops. Chronic inflammation 
thereby has been shown to trigger liver injury which, if not treated, subsequently 
leads to fibrosis and end stage - cirrhosis.  
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The liver parenchyma of 8 week-old Nemo
∆hepa 
mice is characterized by a high 
amount of infiltrating immune cells. Thus, the total amount and the composition of 
infiltrating cells were analyzed in Nemo∆hepa and Nemo∆hepa/CREMα mice using FACS 
analysis. Evaluation of the myeloid panel, including pro-inflammatory monocytes 
(Figure 10A+B), granulocytes (Figure 10C+D) and CD11b+ dendritic cells (DCs) 
(Figure 10E+F), revealed a trend towards a reduced number of infiltrating myeloid 
cells in Nemo
∆hepa/CREMα compared with Nemo∆hepa mice (Figure 10). However, 
concerning the total amount of cells, only CD11b+ DCs showed a significant 
alteration between Nemo
∆hepa/CREMα and Nemo∆hepa mice. Analysis of the lymphoid 
panel, including CD4+ (Figure 11C) and CD8+ T-cells (Figure 11D), NKT-cells 
(Figure 11E) and B-cells (Figure 11F), confirmed the overall trend observed for the 
myeloid panel. While the amount of CD4+ T-cells and NKT-cells showed a tendency 
to be lower in Nemo
∆hepa/CREMα compared with Nemo∆hepa mice, the reduction of 
CD8+ T-cells in Nemo∆hepa/CREMα mice was significant (Figure 11D). In contrast, the 
amount of B-cells showed no alteration in Nemo
∆hepa/CREMα mice (Figure 11F). 
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Figure 10 I Infiltration of myeloid cells in livers of 8 week-old mice 
FACS Analysis for infiltrating myeloid derived cells A) Gating strategy for inflammatory monocytes B) 
Absolute number inflammatory monocytes C) Gating strategy for Granulocytes D) Absolute number of 
Granulocytes E) Gating strategy for CD11b+ DCs F) Absolute number of CD11b+ DCs (Nemo∆hepa vs. 
Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=8-13 mice per group (*p< 0.05). 
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Figure 11 I Infiltration of lymphoid cells in livers of 8 week-old mice 
FACS Analysis for infiltrating lymphoid cells A) Gating strategy for T-cells, NKT-cells and NK-cells B) 
Gating strategy for CD4+ and CD8+ T-cells C) Absolute number of CD4+ T-cells D) CD8+ T-cells E) 
NKT-cells E) B-cells (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=8-13 
mice per group (*p< 0.05). 
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4.3 Tumor development in Nemo∆hepa/CREMα mice 
 
 
Figure 12 I HCC development in 52 week-old mice 
A) Liver pictures and average liver size. B) Serum aspartate aminotransferase (AST) levels 
(Nemo∆hepa vs. Nemo∆hepa/CREMα). C) Liver vs. body weight (LW/BW) ratio (Nemo∆hepa vs. 
Nemo
∆hepa
/CREMα). Data are shown as mean ± SD of n=6-12 mice per group (*p<0.05, **p<0.01). 
 
Nemo
∆hepa
 mice spontaneously develop tumors within a lifetime of one year (21). 
Therefore, tumor initiation and development were investigated in 52 week-old 
animals and compared with Nemo
∆hepa
/CREMα mice. As shown, solid tumors 
developed in both Nemo
∆hepa
 and Nemo
∆hepa
/CREMα mice (Figure 12A). 
Nevertheless, Nemo
∆hepa
/CREMα mice manifested a tendency towards reduced liver 
size compared with Nemo
∆hepa
 (Figure 12A). This observation was supported by the 
fact that the liver versus body weight ratio (Figure 12C), as well as the liver weight 
(data not shown) were significantly reduced in Nemo
∆hepa
/CREMα compared with 
Nemo
∆hepa
 mice. 
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Figure 13 I Histological analysis of liver - nodular tissue  
A) Microscopical picture of H&E staining (scale bar: 200 µm) B) Histological analysis of the tumor load; 
Quantification of number and relative area of HCC and premalignant lesions (PML). Data are shown 
as mean ± SD of n=9-12 mice per group (*p< 0.05). 
 
Subsequently, also the AST values were significantly lower in Nemo
∆hepa
/CREMα 
mice (Figure 12B). Histopathological analysis of H&E stained liver tissue revealed a 
slight, but not significant, increase in the number of premalignant lesions (PML) in 
Nemo
∆hepa
/CREMα mice while the number of HCCs showed no difference between 
Nemo
∆hepa
/CREMα and Nemo
∆hepa
 mice (Figure 13A+B). Accordingly, the area 
classified as PMLs was significantly larger in Nemo
∆hepa
/CREMα mice, whereas the 
area classified as HCC was significantly larger in Nemo
∆hepa
 mice – indicating a 
delayed tumor progression in Nemo
∆hepa
/CREMα mice.  
In line with these data, the number of proliferating cells was significantly reduced in 
Nemo
∆hepa
/CREMα compared with Nemo
∆hepa 
mice as assessed by Ki-67 
immunofluorescence staining (Figure 14A+C). Furthermore, protein levels of the 
proliferation markers PCNA and Cyclin A were attenuated in Nemo
∆hepa
/CREMα mice 
(Figure 14B). However, mRNA levels for Pcna were not affected by the expression of 
the CREMα transgene (Figure 14D). The retinoblastoma (Rb) protein has been 
shown to function as a tumor suppressor. By inhibiting the cell cycle progression it 
prevents excessive cell growth. Once phosphorylated it becomes inactive and  
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Figure 14 I Measurement of proliferation markers in livers of 52 week-old mice 
A) Immunofluorescence staining for Ki-67 (red: Ki-67, blue: DAPI, scale bar: 200 µm). B) Western Blot 
from liver protein for PCNA, Cyclin A, pRb and GAPDH. C) Quantification of Ki-67 positive cells 
(Nemo∆hepa vs. Nemo∆hepa/CREMα) Data are shown as mean ± SD of n=5-11 mice per group (*p< 
0.05). D) q-PCR for Pcna. Data are shown as mean ± SD of n=5-7 mice per group. 
 
therefore allows cell cycle progression (78). Hence the phosphorylation status of Rb 
was determined via Western Blot. In line with the previous data Nemo
∆hepa
/CREMα 
mice display reduced protein levels of pRb (Figure 14B). 
Glutamine synthetase (GS) is an enzyme which catalyzes the synthesis of glutamine 
from glutamate and ammonia and is expressed around the portal veins under healthy 
conditions (79). However, GS is up-regulated in human and murine HCC tissue and 
therefore considered as a marker protein for HCC (80–82). Thus the expression of  
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Figure 15 I Tumorigenesis-associated markers in livers of 52 week-old mice 
A) Immunohistochemical staining for glutamine synthetase (GS) (scale bar: 200 µm). B) Western Blot 
from liver protein for GS and GAPDH. mRNA expression for C) c-myc and D) Afp (Nemo∆hepa vs. 
Nemo
∆hepa
/CREMα). Data are shown as mean ± SD of n=6-11 mice per group (**p< 0.01). 
 
GS was investigated in liver tissues of 52 week-old mice. Immunohistochemical 
staining (Figure 15A) and the quantification via Western blot (Figure 15B) revealed 
increased GS levels in the livers of Nemo
∆hepa 
in comparison to the livers of 
Nemo
∆hepa
/CREMα mice. C-myc is a transcription factor which has been associated 
with the conversion of preneoplastic liver lesions into HCC (83,84). mRNA expression 
levels of c-myc were significantly reduced in Nemo∆hepa/CREMα mice compared with 
Nemo
∆hepa 
mice (Figure 15C), thereby supporting the previous findings. In contrast, 
the expression levels of alpha-fetoprotein (Afp), a clinically used marker for HCC, 
remained unchanged in Nemo
∆hepa 
and Nemo
∆hepa
/CREMα mice (Figure 15D).  
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4.4 The simultaneous transfer of CREMα transgene T-Cells and hematopoietic 
cells reduces liver injury Nemo
∆hepa mice  
 
 
Figure 16 I Cell transfer scheme 
The transplantation was performed as described in 3.1.5. 
A) Outline for the transplantation experiment. B) PCR from tail tissue for CREMα before and after 
transplantation of CREMα transgene T-Cells and bone marrow. 
 
In order to confirm that the observed reduction of liver injury was due to the immune 
cell compartment, especially T-Cells, an adoptive transfer experiment was performed. 
6 week-old recipient mice were irradiated and transplanted with BMDCs. Furthermore 
these animals received a boost injection of T-cells. To assess the impact of the 
transplanted cells on hepatic injury and fibrosis development, the mice were 
sacrificed 8 weeks later (Figure 16A). Successful transplantation was confirmed by 
tail PCR for CREMα in Nemo∆hepa mice before and after transplantation of transgene 
expressing cells (Figure 16B). 
The liver parenchyma of Nemo
∆hepa mice that received CREMα transgene cells 
showed less destruction compared with Nemo
∆hepa mice that received WT cells, as 
assessed by H&E staining (Figure 17A). Additionally, evaluating serum 
transaminases revealed a significant reduction in ALT levels in Nemo∆hepa mice that 
received CREMα transgene cells compared with Nemo∆hepa mice receiving WT cells 
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Figure 17 I Assessment of liver injury in chimeric mice 
To investigate the degree of liver injury, mice were sacrificed 8 weeks after transplantation. 
A) Microscopical picture of H&E staining (scale bar: 200 µm) B) Serum alanine aminotransferase 
(ALT) levels (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=5-11 mice per 
group (**p< 0.01). 
 
(Figure 17B). Consequently, Nemo∆hepa mice receiving CREMα transgene cells 
displayed a reduction in collagen fibers deposition as demonstrated by Sirius red 
staining (Figure 18A). Quantification of Sirius red positive area revealed a significant 
reduction (Figure 18B). 
 
Figure 18 I Fibrosis development in chimeric mice 
A) Immunohistochemical staining for Sirius red (scale bar: 200 µm) B) Quantification of Sirius red-
positive area (WT>Nemo∆hepa vs. CREMα>Nemo∆hepa). Data are shown as mean ± SD of n=5-11 mice 
per group (**p< 0.01) 
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4.5 The expression of CREMα changes the inhibitory profile of T-cells 
 
Several studies indicate that IL-17 is a pro-inflammatory as well as a pro-fibrotic 
cytokine. Interestingly, Nemo∆hepa/CREMα mice did not show an aggravation of liver 
injury. Thus FACS analysis for Rorγ was performed in hepatic leukocytes to ensure 
the presence of a TH17 phenotype in these mice. Unexpectedly, there was no 
difference in Rorγt expression in Nemo
∆hepa/CREMα compared with Nemo∆hepa mice 
(Figure 19A). In order to investigate whether this was a general feature of the 
transgene expressing T- cells or organ specific q-PCR for Rorγt and Il17A in hepatic 
vs. splenic T-cells was performed. My results revealed that hepatic T-cells of CREMα 
control mice showed a significantly increased mRNA expression of Rorγt compared 
with WT mice while the mRNA expression was significantly decreased in 
Nemo
∆hepa/CREMα compared with CREMα control and Nemo∆hepa mice (Figure 19B). 
Nonetheless, Il17A mRNA levels of hepatic T-cells were not affected by the 
expression of CREMα (Figure 19B). In contrast, T-cells isolated from spleens of 
Nemo
∆hepa/CREMα mice showed a significant increase, in the mRNA expression of 
Rorγt and Il17A (Figure 19B). Altogether mRNA levels of Rorγt and Il17A were 
increased in hepatic T-cells compared with splenic T-cells (Figure 19B). The results 
for the differentiation of hepatic T-cells into TH17 lineage were confirmed by absolute 
quantification of mRNA transcripts using the ncounter® analysis system (Figure 
19C). 
Regulatory T-cells (Treg) are a subset of T-helper cells which are developmentally 
closely related to TH17-cells. In vitro, the stimulation of T-cells with TGF-β leads to 
the development of Tregs (85,86), while the stimulation with TGF-β and IL-6 leads to 
the development of TH17-cells (86). Thereby Forkhead-box protein P3 (FOXP3), the 
lineage transcription factor for Tregs (87–89) suppresses the expression of Rorγt and 
vice versa (86,90). For this reason both cell types are thought to compete for naïve T-
cell differentiation. Thus the differentiation of hepatic T-cells into Tregs was 
investigated using the ncounter® analysis system. The results showed that the 
absolute number of mRNA transcripts for foxp3 was increased in Nemo
∆hepa/CREMα  
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Figure 19 I T helper cell differentiation 
To assess the gene expression profile of T-Cells, hepatic and splenic T-Cells were isolated using 
MACS technique, as described in 3.8. 
A) FACS analysis for Rorγt in hepatic leukocytes. B) q-PCR for Rorγt and Il17A in hepatic vs. splenic 
T-cells (WT vs. CREMα, CREMα vs. Nemo∆hepa/CREMα, Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are 
shown as mean ± SD of n=2-5 mice per group (*p< 0.05, **p< 0.01). 
Results from ncounter® analysis were subjected to pathway analysis by Ingenuity software (NIH, 
Bethesda) and analyzed for the differentiation of hepatic T-cells into C) TH17 lineage and D) Tregs. E) 
q-PCR for Treg-associated markers in in hepatic T-cells (Nemo∆hepa vs. Nemo∆hepa/CREMα). Data are 
shown as mean ± SD of n=2-5 mice per group (*p<0.05). 
 
compared with Nemo
∆hepa
 mice (Figure 19D). Further gene expression analysis 
revealed a significant increase of the inhibitory cytotoxic t-lymphocyte antigen-4 (Ctla-
4) in Nemo∆hepa/CREMα mice (Figure 19E). Furthermore, the mRNA expression of 
Il10, the marker cytokine of Tregs, was strongly, but not significantly, increased in T-
cells of CREMα transgene expressing Nemo∆hepa mice (Figure 19E).  
To further confirm these observations, FACS-analysis for FOXP3, CTLA-4 and T-cell 
immunoglobulin domain and mucin domain 3 (TIM3) were performed. In order to 
address the question if the observed changes are exclusive for hepatic T-cells blood-
derived T-cells were included into the analysis (the gating strategy for the experiment 
is displayed in Figure 20A). The analysis revealed a slight induction of Tregs, as 
assessed by FOXP3 expression, in hepatic CD4+ T-cells of Nemo∆hepa and a 
significant induction of FOXP3 in hepatic CD4+ T-cells of Nemo∆hepa/CREMα mice 
(Figure 20B). The percentage of FOXP3 expressing CD8+ T-cells was significantly 
increased in hepatic CD8+ T-cells compared with blood-derived CD8+ T-cells in both 
groups (Figure 20C). However, in hepatic CD8+ T-cells the expression of FOXP3 
was slightly reduced in Nemo∆hepa/CREMα mice compared with Nemo∆hepa mice 
(Figure 20B). Accordingly, a similar expression pattern was observed for CTLA-4 
expression on CD4+ T-cells (Figure 20D). Interestingly, in Nemo∆hepa/CREMα mice 
CTLA-4 was strongly induced in hepatic CD4+ T-cells compared with blood-derived 
CD4+ T-cells. This induction was found to be highly significant (Figure 20D). 
Furthermore, although, generally expressed to a lower extend on CD8+ T-cells,  
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Figure 20 I FACS-Analysis of inhibitory T-cell epitopes in hepatic vs. blood-derived T-cells 
A) Gating strategy for FOXP3+ and CTLA-4+ CD4+ T-cells B) percentage of CD4+ FOXP3+ T-cells, 
C) percentage of CD8+ FOXP3+ T-cells, D) percentage of CD4+ CTLA-4+ T-cells, E) percentage of 
CD8+ CTLA-4+ T-cells F) percentage of CD4+ TIM3+ T-cells, G) percentage of CD8+ TIM3+ T-cells 
(Nemo∆hepa vs. Nemo∆hepa/CREMα, Nemo∆hepa vs. Nemo∆hepa, Nemo∆hepa/CREMα vs. 
Nemo∆hepa/CREMα). Data are shown as mean ± SD of n=8-13 mice per group (*p< 0.05, **p< 0.01, 
***p< 0.001). 
 
CTLA-4 was significantly induced on hepatic CD8+ T- cells in comparison to blood-
derived CD8+ T-cells. However, an induction of CTLA-4 was observed in CD8+ T-
cells of Nemo
∆hepa/CREMα as well as of WT and Nemo∆hepa mice (Figure 20E). TIM3 
is another molecule related to the inhibitory properties of Tregs (91). In line with the 
previous data, TIM3 was strongly induced on hepatic CD4+ and CD8+ T-cells in 
comparison to blood-derived CD4+ (Figure 20F) and CD8+ T-cells (Figure 20G). 
Although observed in all investigated genotypes, the induction of TIM3 on CD4+ and 
especially on CD8+ T-cells was most prominent and significantly higher in 
Nemo
∆hepa/CREMα mice compared with Nemo∆hepa mice and already observed in 
blood derived CD8+ T-cells (Figure 20G). Moreover, the percentage of hepatic CD8+ 
TIM3 expressing T-cells was up to four-fold higher than the percentage of hepatic 
CD4+ TIM3 expressing T-cells (Figure 20F+G). 
In order to investigate whether the observed alterations of Treg associated markers 
was mediated by the expression of CREMα in CD2-expressing cells, the data from 
the ncounter® analysis were reevaluated with special consideration to co-stimulatory 
and co-inhibitory T-cells epitopes (Figure 21). This revealed a down-regulation of co-
stimulatory molecules such as Cd28 (92) or Cd53 (93) in hepatic T-cells derived from 
CREMα in comparison to WT mice (Figure 21A). This reduction was more 
pronounced in hepatic T-cells of Nemo
∆hepa
 and even more in Nemo
∆hepa/CREMα 
mice (Figure 21A). In contrast, although the expression of Foxp3 was only slightly 
regulated in hepatic T-cells of CREMα compared with WT mice, molecules related to 
Treg function such as Ctla-4 and Epstein-Barr virus induced gene 3 (Ebi3) (94) were 
up-regulated in hepatic T-cells of CREMα mice (Figure 21B). Consistently, 
Programmed cell death protein 1 (Pdcd1), a surface receptor that prevents the 
activation of T-cells  
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Figure 21 I Determination of the inhibitory profile of hepatic T-cells 
Heat map for A) co-stimulatory and B) co-inhibitory T-cells epitopes. The expression of genes related 
to the inhibitory profile of T-cells was represented using Multi Experiment Viewer software (MeV). The 
hierarchical gene clustering was obtained by Pearson Test Correlation (FC<1.5), (Red: up-regulated; 
Green: down-regulated).  
 
by inhibiting Treg apoptosis was also up-regulated in hepatic T-cells of CREMα mice 
(Figure 21B).  
Additionally, other molecules related to immune cell inhibition like the Collagen 
inducible leukocyte-associated immunoglobulin-like receptor 1 (Lair1) (95) were up-
regulated in hepatic T-cells of CREMα mice. The amount of up-regulated, co-
inhibitory molecules on hepatic T-cells was further increased in Nemo
∆hepa compared 
with WT and mice CREMα (Figure 21B). However, Ctla-4 and Ebi3 showed the 
strongest induction in hepatic T-cells of Nemo
∆hepa
/CREMα mice (Figure 21B). 
Moreover, T cell immunoreceptor with Ig and ITIM domains (Tigit), another molecule 
that mediates the inhibition of T-cells and is able to induce IL-10 production by DCs 
(96) was also strongly up-regulated in hepatic T-cells of Nemo
∆hepa
/CREMα mice 
(Figure 21B). Importantly, none of the co-inhibitory molecules investigated, was 
expressed higher in Nemo
∆hepa in comparison to Nemo
∆hepa
/CREMα mice. 
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4.5 Assessment of myeloid derived suppressor cells (MDSCs) 
 
 
Figure 22 I Quantification of myeloid-derived suppressor cells 
A) Gating strategy for MDSCs B) FACS analysis for MDSCs (Nemo∆hepa vs. Nemo∆hepa/CREMα). 
Data are shown as mean ± SD of n=7-12 mice per group. 
 
Myeloid derived suppressor cells (MDSCs) are important players in the regulation of 
the immune system. Recently, it was demonstrated that a reduced number of hepatic 
MDSCs is responsible for the aggravated susceptibility of CREMα mice to ConA 
induced hepatitis (44). In order to investigate a possible involvement of MDSCs in the 
phenotype observed in Nemo
∆hepa
/CREMα mice, the amount of intrahepatic MDSCs 
was determined by performing FACS-analysis. Therefore, MDSCs were defined, as 
already published, as CD45+, CD3-, GR1+, CD11b+ and either CD2+ (monocytic 
MDSCs) or CD2- (granulocytic MDSCs) (44). The gating strategy for both cell 
populations is shown in Figure 22A. The analysis revealed that WT and CREMα mice 
exhibit a similar amount of MDSCs. In contrast, Nemo∆hepa/CREMα mice showed a 
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slight reduction in the total amount of MDSCs compared to Nemo∆hepa mice (Figure 
22B). However, this reduction did not reach statistical significance. 
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5. Discussion 
 
Nemo∆hepa mice are characterized by the development of CLD, originating from 
spontaneous hepatocyte apoptosis and compensatory proliferation. Thereby, a 
strong inflammatory response is thought to trigger disease progression, finally 
leading to HCC development. In the current study, I demonstrated that the 
expression of CREMα in CD2-expressing cells ameliorates disease progression in 
Nemo∆hepa mice, since I found a reduction of liver injury and fibrosis-related markers. 
Moreover, Nemo
∆hepa/CREMα mice displayed reduced tumorigenesis and less HCC. 
Investigating the underlying mechanism I found interesting alterations in the 
expression pattern of molecules, related to inhibitory T-cell function. In the following I 
will therefore discuss the data with special regards to TH17 and regulatory T-cells. 
 
5.1 The milieu in livers of Nemo∆hepa mice changes the TH17 phenotype of 
CREMα-expressing mice and favors a Treg response 
 
CREMα-expressing T-cells are characterized by the presence of a TH17 phenotype. 
In vitro, these cells show an enhanced expression of the lineage transcription factor 
RORγt and the marker cytokines IL-17, IL-21, IL-22 and IL-23, even in the absence of 
TH17 inducing conditions (41). In vivo studies further revealed an increased 
inflammation and an enhanced production of TH17 related cytokines in models of 
contact dermatitis and acute lung injury in CREMα mice (41,43). 
However, the present study indicates that this TH17 phenotype might be changed 
upon hepatic Injury. In accordance with the published data, T-cells isolated from 
spleens of CREMα-expressing mice, showed increased mRNA expression of RORγt 
and IL-17 (Figure 19). Thereby, the expression of RORγt and IL-17 were strongly 
increased in hepatic T-cells in comparison to splenic T-cells. In line with this 
Hammerich et al. found a higher expression of the CREMα transgene in hepatic T-
cells in comparison to splenic T-cells (44). However, as this was already published I 
analyzed only few mice, in order to confirm my observations in Nemo
∆hepa/CREMα 
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mice. Surprisingly, the expression of RORγt in hepatic T-cells was significantly down-
regulated in Nemo∆hepa/CREMα compared with CREMα and Nemo∆hepa mice. Thus I 
performed FACs analysis to quantify the percentage of RORγt expressing T-cells in 
the liver and found no differences in RORγt levels in Nemo∆hepa compared with 
Nemo
∆hepa/CREMα mice (Figure 19). In line with these observations, IL-17 mRNA 
levels were not altered in hepatic T-cells. 
Tregs represent a CD4+ population which regulates immune responses. Tregs can 
be either generated in the thymus (nTregs) or alternatively they can be induced in the 
periphery (iTregs) (97). Importantly, TH17 cells and Tregs develop via reciprocal 
pathways. Thus, the differentiation process of TH17 cells inhibits Treg differentiation 
and vice versa (86,90,97–101). Due to this fact I questioned whether the reduced 
expression of RORγt might have been due to an increase in hepatic Tregs. Indeed, I 
found increased mRNA levels of the lineage transcription factor FOXP3 (Figure 19-
21). Furthermore the mRNA expression of IL-10, which is implicated in Treg 
mediated suppression (97,100,102,103), was increased in Nemo∆hepa/CREMα 
compared with Nemo
∆hepa
 mice. Moreover, the mRNA expression level of CTLA-4, a 
molecule that has been shown to be related to Treg function (104,105) was 
increased. To further investigate this direction I performed FACS analysis to 
determine the percentage of FOXP3+ cells in hepatic and peripheral leukocytes. The 
results show that the percentage of hepatic FOXP3+ T-cells was increased in 
Nemo
∆hepa/CREMα compared with Nemo∆hepa mice – a phenomenon which I did not 
observe in blood-derived T-cells (Figure 20). 
The reduction of RORγt mRNA levels and the increased percentage of FOXP3+ and 
CTLA-4+ in hepatic T-cells from Nemo∆hepa/CREMα mice raised the question whether 
the inflammatory milieu in Nemo
∆hepa
 livers exerts a direct effect on CREMα-
expressing T-cells. The liver has been shown to be the major source of iTregs, as a 
mechanism to achieve oral tolerance against antigens delivered from the 
gastrointestinal tract (106). Thereby, different types of liver resident cells, such as 
Kupffer Cells (106), liver dendritic cells (107) and liver sinusoidal endothelial cells 
(LSECs) (108,109) have been shown to successfully induce Tregs. Among these, 
LSECs have been demonstrated to be the most efficient cell type in TGFβ dependent 
hepatic Treg induction (108). This mechanism appears to be of major importance for 
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the induction of oral tolerance but does not explain the increased induction of hepatic 
Tregs that I observed upon injury (Figure 19-21). Several studies indicate that 
activated HSCs, especially during states of inflammation, function as by-stander to 
enhance Treg differentiation (110–113). Upon activation, HSCs trans-differentiate into 
myofibroblasts, a process which is accompanied by the progressive loss of stored 
Vitamin A, which is metabolized to Retinoic Acid (RA)(113,114).  
Ichikawa et al. (111) demonstrated that HSCs promote the differentiation of Tregs. As 
they showed that HSCs do not function as APCs they investigated whether HSCs 
may function as regulatory by-standers. Indeed, they were able to show that the 
induction of FOXP3+ cells was dependent on their ability to produce RA. 
Consequently, treatment with the RARα antagonist LE540 inhibited the induction of 
Treg differentiation (111). Additionally, it was shown that HSCs not only induced the 
differentiation of Tregs in vitro but further suppressed the development of TH17 cells 
by targeting RORγt (98,111). Thereby, this study suggests a reasonable mechanism 
to explain the altered rate of FOXP3 expressing cells in Nemo∆hepa and 
Nemo
∆hepa/CREMα mice, and furthermore the reason for which this effect is limited to 
hepatic T-cells. 
Furthermore, Mucida et al. (98) demonstrated that the addition of RA promoted the 
expression of CTLA-4, not only in CD4+ T-cells but also in CD8+ T-cells in vitro. 
Moreover, T-cells, activated in vitro, in the presence of TGFβ and RA, were able to 
fully rescue induced colitis in mice upon transplantation. Interestingly, the observed 
effects were limited to the use of DCs isolated from mesenteric lymph nodes in in 
vitro experiments and were absent with splenic DCs. This supports my findings in the 
direction that the frequency of FOXP3+ cells is locally increased (Figure 21). Finally, 
the authors showed that adding RA to T-cells, cultured under TH17 stimulating 
conditions, dose-dependently increased the amount of FOXP3+ cells while TH17 
differentiation was decreased. Thus they proposed that under physiological 
conditions, RA-driven TGFβ-dependent Treg differentiation might be able to 
overcome the IL-6 promoted TGFβ-dependent TH17 cell generation (98). These 
findings might explain the absence of the expected TH17 phenotype in 
Nemo
∆hepa/CREMα livers. 
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The differentiation of T-cells, especially Tregs and Th17 cells, is a reversible process. 
Upon treatment with specific cytokines differentiated T-cells can be reprogrammed 
into another T-cell subset, a phenomenon called plasticity (90,115). Thus, the 
presence of RA and TGFβ in Nemo∆hepa livers might represent a sufficient stimulus to 
change the differentiation status of TH17 cells into Tregs. As this effect seems to be 
more pronounced in T-cells of Nemo
∆hepa/CREMα mice, CREMα might increase the 
susceptibility of T-cells for the differentiation into Tregs, likely via RA.  
Alternatively, naive CD4+ or CD8+ T-cells could be differentiated into Tregs by RA 
and TGFβ, produced by HSCs and thereby “steal” precursors of TH17 cells. 
However, the mechanism of how CREMα exerts this effect and whether FOXP3+ T-
cells develop de novo or via re-differentiation remains elusive. One can speculate 
that the observed phenotype may be related to general changes in the expression 
pattern of inhibitory T-cells epitopes that I observed in hepatic T-cells of CREMα mice 
(Figure 21).  
Another possibility to explain the observed reduction of TH17 cells and the following 
increase of Tregs is the crosstalk of two independent mechanisms. Cui et al. 
demonstrated that treatment with a Liver-X-Receptor (LXR) agonist ameliorated 
experimental autoimmune encephalomyelitis (EAE) in mice while LXR deficiency 
exacerbated EAE. They further demonstrated that LXR overexpression/ activation 
decreased in vitro cytokine driven TH17 differentiation in mouse and human T-cells 
(116). Our working group previously demonstrated that the LXR pathway scored 
within the top 20 regulated pathways in the liver tissue of Nemo∆hepa mice (117). This 
raises the possibility that LXR dependent inhibition of TH17 cell differentiation 
suppresses the development of a TH17 phenotype in livers of Nemo
∆hepa
 mice and 
thereby paves the way for the development of Tregs. 
Usually Tregs develop in the presence of TGFβ (85,86), while the differentiation of 
TH17 cells needs the combination of TGFβ and IL-6 (86). However, there is 
evidence, that IL-6 positively regulates FOXP3+ CD8+ T-cell development and 
function under chronic inflammatory conditions. FOXP3+ CD8+ T-cells that 
developed in vivo in the presence of enhanced IL-6 signaling were able to suppress 
the development of a spontaneous TH17 mediated autoimmune arthritis. However, 
only the absolute number of FOXP3+ CD8+ T-cells was increased while the 
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percentage was decreased (118). As the expression of FOXP3 is also increased in 
the hepatic CD8+ T-cell compartment (Figure 20) in Nemo∆hepa and 
Nemo
∆hepa/CREMα mice, the phenotype which I observed in Nemo∆hepa/CREMα mice 
may be partially related to an increased amount of FOXP3+ CD8+ T-cells. 
 
5.2 The expression of CREMα reduces hepatic inflammation and development 
of liver fibrosis in Nemo∆hepa mice   
 
The liver is a central immunological organ and is enriched with immune cells, like 
Kupffer Cells - liver resident macrophages - or NK cells. These cells are able to 
initiate adaptive and innate immune response or immunological tolerance. Upon liver 
injury, as in Nemo∆hepa mice, Kupffer Cells for example can promote inflammation by 
the secretion of proinflammatory mediators such as TNFα or IL-6 as part of a wound 
healing response. These mediators can attract other immune cell populations such 
as T-cells, induce hepatocyte apoptosis and activate HSCs. Nevertheless, if the 
source of liver injury cannot be removed, as it is the case in Nemo∆hepa mice, chronic 
inflammation develops leading to liver injury and fibrosis develops.  
The expression of CREMα under control of the CD2 promoter in mice has been 
shown to reduce the number and alter the composition of hepatic immune cells. 
CREMα mice were highly susceptible to ConA induced hepatitis, although 
intrahepatic numbers of T-cells, NK-cells and macrophages were significantly lower 
compared with WT mice. Nevertheless, the amount of neutrophils and B-cells was 
similar in CREMα mice and WT mice after ConA treatment (44).  
In line with these data, I found a trend towards reduced amounts of proinflammatory 
macrophages, granulocytes and NKT-cells in Nemo∆hepa/CREMα mice. Furthermore 
CD11b+ DCs and CD8+ T-cells were significantly reduced in Nemo∆hepa/CREMα mice 
compared with Nemo
∆hepa
 mice (Figure 10+11) and thus suggesting a reduced 
proinflammatory response. This might be due to the observed induction of Tregs, 
which are potent inhibitors of inflammation (97). Importantly, our working group 
already demonstrated that targeting NK and NKT-cells by administration of a NK1.1 
depleting antibody attenuated the phenotype observed in Nemo∆hepa mice (119). 
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As a consequence of hepatic inflammation HSCs become activated. These cells 
produce extracellular matrix and thereby contribute to the formation of fibrotic scars in 
the liver parenchyma, as observed in 13 week-old Nemo
∆hepa
 mice (Figure 8). The 
interaction of immune cells and HSCs is closely related to the progression of liver 
fibrosis. While NK cells, M2 macrophages, Tregs and bone marrow derived 
CD11b+Gr1+ cells ameliorate liver fibrosis, neutrophils, M1 macrophages, CD8+ T-
cells, NKT cells and TH17 cells promote fibrogenesis (56,120–124).  
In terms of CD4+ T-cells, the role of TH17 cells in liver fibrosis was investigated 
thoroughly and it has been demonstrated that TH17 cells contribute to tissue damage 
by secreting cytokines such as IL-17 and IL-22. In the liver IL-17 was shown to 
induce inflammation and to stimulate fibrosis development while IL-22 promotes 
hepatocyte survival and proliferation (56,125). In vitro, IL-22 has been shown to 
stimulate HSCs to produce chemokines, which promoted Th17 cell chemotaxis and 
therefore exacerbates hepatic inflammation (126). TH17 cells are not the only 
producers of IL-17, even though they represent the major source. Neutrophils, CD8+ 
T-cells, NK cells and γδ T-cells also secrete IL-17 (101,127). Consequently, depletion 
of IL-17 signaling has been shown to limit inflammation and subsequent hepatocyte 
damage in mice (55). In line, increased IL-17 signaling exacerbates CCl4 and BDL 
induced liver fibrosis in mice by promoting HSCs activation, leading to increased 
Collagen deposition. Consequently, inflammation and fibrosis were ameliorated in IL-
17 KO mice (56,57). In contrast, Tregs have been shown to suppress TH17 mediated 
inflammation via IL-10 signaling and STAT3 (99,100). Consequently, several studies 
demonstrated that Tregs limit fibrosis development by suppressing excessive 
immune responses in different organs such as liver, heart and lung (122,128–130). 
Thus, the increased frequency of Tregs in Nemo∆hepa/CREMα mice might be 
responsible for the reduced number or rather the compositional changes of immune 
cells. Consequently, Collagen deposition and HSCs activation were found to be 
reduced in Nemo
∆hepa/CREMα mice (Figure 8+9). Nevertheless, various immune cell 
populations such as B-cells, different T-cell subsets, macrophages, DCs and 
neutrophils are capable of producing IL-10 (131). Therefore I cannot exclude that 
infiltrating leukocytes besides Tregs contribute to the increased levels of IL-10, 
especially due to the fact that, in contrast to the initial assumption, not only T-cells 
express the CREMα transgene (44,68,69). 
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To further prove that bone marrow derived cells (BMDCs) are responsible for the 
ameliorated liver injury and fibrogenesis in Nemo∆hepa/CREMα mice I performed BMT 
(described in 3.1.5). To strengthen the effect, which I thought is mainly T-cell 
mediated, I additionally transferred splenic T-cells to boost the T-cell response. 
Confirming my previous findings, Nemo∆hepa mice that were reconstituted with 
CREMα BMDCs displayed a significant reduction in injury marker ALT (Figure 17) as 
well as reduced fibrogenesis (Figure 18) in comparison to Nemo∆hepa mice 
reconstituted with WT BMDCs.  
However, it was recently demonstrated that all major lymphocyte subsets express 
high levels of the CREMα transgene including MDSCs (44) and the protective effect 
observed in Nemo
∆hepa/CREMα mice might be most likely mediated by a complex 
interplay of various immune cell types. Additionally, the chronic inflammatory milieu 
present in Nemo
∆hepa
 mice seem to exert an effect on CREMα transgene cells and 
thereby modulates the immune response. 
 
5.3 The expression of CREMα ameliorated tumor initiation and progression in 
Nemo∆hepa mice   
 
Many types of cancer such as HCC, colon carcinoma or stomach cancer have been 
shown to be associated to infections and arise from sites of chronic inflammation. 
Persistent tissue damage, either by infections or, as in Nemo∆hepa mice, due to 
continuous hepatocyte apoptosis causes a chronic inflammatory response and leads 
to sustained tissue regeneration. Substances released by immune cells such as 
reactive oxygen species interact with DNA in proliferating cells, resulting in an 
accumulation of genomic alterations. Thereby chronic inflammation triggers the 
development of cancer (132).  
Additionally, tumors themselves produce numerous cytokines and chemokines in 
order to recruit leukocytes which in turn produce an array of cytokines, cytotoxic 
mediators, growth factors and DNA-damage promoting substances. Thus tumors are 
capable of modulating their microenvironment in order to promote angiogenesis, 
tissue invasion or to escape from immune response (133).  
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One mechanism for the immune evasion of tumors is the attraction of Tregs via 
CCL22/CCR4 (134) and the induction of Tregs by prostaglandin E2 (135) or H-ferritin 
(136). Elevated numbers and increased suppressive function have been shown in 
various murine cancer models such as a colon carcinoma model (137), a prostate 
dysplasia model (138) and a lung cancer model (135). Consequently, the depletion of 
Tregs by monoclonal antibodies or drugs as cyclophosphamide caused regression of 
melanomas (139), mammary gland tumors (140) and delayed the outgrowth of 
tumors in rat colon cancer (141) (Table 20). Additionally, a number of human studies 
has demonstrated increase frequencies of Tregs in patients suffering from non-small 
cell lung cancer (142), ovarian cancer (134), invasive breast cancer & pancreas 
cancer (143), metastatic melanoma (144), gastric cancer (145) and importantly also 
HCC (146). Furthermore, hematologic malignancies have been associated with 
increased numbers of Tregs (147). Thereby, an increase of Tregs has been shown to 
promote tumor growth and was often closely correlated to poor prognosis and 
decreased survival rates. Moreover several studies indicate that this effect was 
associated with the suppression of a potent antitumor immunity, especially via 
decreasing the CD8+ T-cell population (148,149). Tregs in human tumors such as 
HCC, cervical, colorectal and ovarian cancer, are further defined by the expression of 
TIM3 (150,151). Sakuishi et al. demonstrated that TIM3 is a key regulator of 
dysfunctional or exhausted CD8+ T-cells and that the co-blockage of TIM3 and PD-1 
signaling pathways reversed T-cell exhaustion and inhibited Treg functions in tumor 
tissues (151). As the amount of FOXP3+, CTLA-4 and TIM3+ T-cells is increased in 8 
week-old Nemo
∆hepa/CREMα mice (Figure 20) they consequently develop more 
premalignant lesions as observed in Nemo∆hepa mice (Figure 13). However, the 
conversion from premalignant lesions into HCC was inhibited in Nemo∆hepa/CREMα 
mice. Nevertheless, the role of Tregs in tumorigenesis is a double-edge sword. 
Stewart et al. showed that type I IFN dependent production of IL-10 by Tregs 
suppresses tumor TH17 inflammation in murine transplantable tumor models like 
Lewis lung carcinoma and MC38 colon carcinoma (152). The progression of HCC is 
associated to increased numbers of intra-tumoral Th17 cells in humans and mice 
(63,152), and correlates with a bad prognosis in different types of cancer (153–156). 
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Table 20 I Methods to deplete Tregs and their effect in different tumor models. 
Therapy Effect on Tumor 
CD25 mAB 
Induction of tumor specific CD8+ effector cells and NK cells (157) 
Tumor regression in mammary gland tumor model but increased 
susceptibility to experimental autoimmune thyroiditis (140) 
CD25 + CTLA-4 mAB 
Synergistic effect, maximum tumor rejection in a murine 
melanoma model  
Efficacy of the antitumor therapy correlated with the extent of 
autoimmune skin depigmentation (139) 
Cyclophosphamide Delayed outgrowth in rat colon cancer (141) 
COX2 inhibitors Decreased tumor burden in lung cancer models (135) 
 
As already discussed above, the inflammatory milieu in Nemo
∆hepa
 mice might, 
dependent on the CREMα transgene, alter the ratio between Tregs and TH17 cells. 
Thus RA/LXR mediated suppression of CREMα transgene TH17 cells in combination 
with an increased frequency of Tregs probably contributes to the reduced size of 
HCCs in Nemo∆hepa/CREMα mice. However, the contribution of TH17 cells to tumor 
formation is still not clear and under current debate (158).  
In a murine model for pancreatic cancer and in patients with breast cancer the 
induction of TH17 cells in the microenvironment improved the survival rate (159). 
Additionally, patients with breast cancer have been shown to benefit from increased 
numbers of TH17 cells as they were negatively associated to tumor stage, blood 
vessel invasion, and numbers of metastatic lymph nodes (160). Furthermore it was 
demonstrated that TH17 cells can elicit a protective inflammatory response, which 
includes the activation of tumor specific CD8+ T-cells (161).  
MDSCs are a cell population which has recently been described to express CD2 and 
to be responsible for the increased susceptibility to ConA-mediated hepatitis in 
CREMα mice (44). MDSCs have been first identified in tumor bearing hosts (162) 
and expansion of MDSCs is frequently observed in murine tumor models and patient 
samples (163,164). Thus the elimination of MDSCs led to direct anti-tumor effects in 
some models by improving the immune response against tumor tissues (163,165). 
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Additionally, MDSCs exert their effects not only on immune cells but further have 
been demonstrated to promote angiogenesis (166) and metastasis (167).  
MDSCs cells are characterized by surface expression of CD11b and GR1 in mice 
(168) and known to suppress T-cell proliferation and cytokine production (169) while 
they can induce Tregs (170,171). MDSCs are subdivided into two major 
subpopulations. Hepatic, as well as splenic monocytic MDSCs (mMDSCs) show a 
low SSC profile and express low levels of Gr1, while granulocytic MDSCs (gMDSCs) 
have a higher SSC profile and express high levels of GR1(44,168,169). Additionally, 
mMDSCs, which are the principle immunosuppressive MDSC population during 
tumor growth (172), express CD2, while gMDSCs do not (44,169).  
In line with the data from ConA-induced hepatitis (44) the number of MDSC tended to 
be reduced in Nemo
∆hepa/CREMα mice (Figure 22). As the authors further observed a 
CREMα dependent reduction of the inhibitory functions in CD2-expressing mMDSCs 
(44), one can speculate that this might also apply for Nemo∆hepa/CREMα mice. 
Therefore a CREMα mediated down-regulation of mMDSCs number and function 
could be a reason contributing to reduced HCC development in Nemo∆hepa/CREMα 
mice. 
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5.4 Final conclusions and outlook 
 
The current study demonstrates that a reduction of the inflammatory status in 
Nemo
∆hepa
 mice ameliorates the progression of chronic liver disease, leading to 
reduced fibrogenesis and HCC development. However, the same mechanism that 
exerts beneficial effects at the onset of the disease might deteriorate disease 
progression in more advanced stages by impairing an effective anti-tumor immune 
response. Thus timing of immunosuppression in the development of inflammation 
associated cancers seems to be of major importance. As I obtained only data from 8 
week-old mice concerning the presence of inhibitory cell populations, additional in 
vivo studies are needed to investigate the composition of hepatic immune cells with 
special regards to the role of MDSCs and Tregs during hepatocarcinogenesis in 
Nemo
∆hepa
 mice.  
This study further demonstrates that inflammation is only a trigger of carcinogenesis 
in Nemo
∆hepa
 mice, and that the degree of immune-suppression that I observed in 
Nemo
∆hepa/CREMα mice was not sufficient to prevent HCC development, further 
underlining the key role of persistent hepatocyte apoptosis and the following 
compensatory proliferation for carcinogenesis in Nemo∆hepa mice. Therefore, detailed 
studies are needed to identify the right degree of immunosuppression to prevent the 
development of inflammation associated cancers while maintaining a sufficient anti-
autoimmune response.  
In the future, the effects of the CREMα transgene should be investigated in more 
detail using in vitro studies in order to prove Treg induction by activated HSCs, 
especially in CREMα transgene T-cells. Further studies are needed in order to 
dissect the role of the CREMα transgene in changing the inhibitory profile and the 
influence onto the effector functions of various suppressive cell types, especially 
under acute and chronic inflammatory conditions.  
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